

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07K 7/08, A61K 39/00, 37/02 G01N 33/569</p>	<p>A1</p>	<p>(11) International Publication Number: WO 90/13563 (43) International Publication Date: 15 November 1990 (15.11.90)</p>
<p>(21) International Application Number: PCT/CA90/00135 (22) International Filing Date: 26 April 1990 (26.04.90) (30) Priority data: 344,565 28 April 1989 (28.04.89) US (71) Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA [CA/CA]; 1-3 University Hall, Edmonton, Alberta T6G 2J9 (CA). (72) Inventors: HODGES, Robert, S. ; 4111 - 111B Street, Edmonton, Alberta T6J 1J7 (CA). PARANCHYCH, William ; 5415 - 142 Street, Edmonton, Alberta T6H 4B7 (CA). LEE, Kok, K. ; 1-3 University Hall, Edmonton, Alberta T6J 2J9 (CA). PARAML, Sastry, A. ; 2451 - 115 Street, Edmonton, Alberta T6J 4Z2 (CA). IRVIN, Randall, T. ; 411 Pheasant Run, Mississauga, Ontario L5L 2C2 (CA). DOIG, Peter, C. ; 30 Charles Street West, Apt 1612, Toronto, Ontario M4Y 1R5 (CA).</p>		<p>(74) Agent: WOODLEY, John, H.; Sim & McBurney, Suite 701, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), + CH, CH (European patent), CM (OAPI patent), DE, + DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: SYNTHETIC PSEUDOMONAS AERUGINOSA PILIN PEPTIDE AND RELATED VACCINES AND DIAGNOSTICS (57) Abstract Treatment and diagnosis of <i>P. aeruginosa</i> infection or colonization is achieved in accordance with this invention by the discovery of a polypeptide which is smaller than the naturally occurring <i>P. aeruginosa</i> pilin protein. The pure polypeptide comprises at least one amino acid residue sequence containing about twelve amino acid residues and up to about twenty amino acid residues that define a sequence capable of immunologically mimicking an antigenic determinant site of <i>P. aeruginosa</i> pilin. This amino acid residue sequence can repeat as a unit one or more times in the same polypeptide molecule. More than one of such repeating units and more than one repeating unit of the same type can be present in a single polypeptide molecule. The polypeptides act as antigens or immunogens and antibodies may be raised to the immunogens and a vaccine prepared suitable for the prevention of <i>P. aeruginosa</i> infection.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

**SYNTHETIC *PSEUDOMONAS AERUGINOSA* PILIN PEPTIDE
AND RELATED VACCINES AND DIAGNOSTICS**

FIELD OF THE INVENTION

5 This invention relates to antigens, immunogens and to vaccines utilizing such immunogens. More particularly, this invention relates to polypeptide antigens or immunogens, antibodies raised by such immunogens, and a vaccine suitable for the prevention of *P. aeruginosa* infection or colonization.

10 **BACKGROUND OF THE INVENTION**

During the past two decades, *Pseudomonas aeruginosa* has been recognized as a pathogen which causes between 10% and 20% of infections in most hospitals. *Pseudomonas* infection is especially prevalent among patients with burn wounds, cystic fibrosis, acute leukemia, organ transplants, and intravenous-drug addiction. *P. aeruginosa* is a common nosocomial contaminant, and epidemics have been traced to many items in the hospital environment. Patients who are hospitalized for extended periods are frequently affected by this organism and are at increased risk of developing infection. The most serious infections include malignant-external otitis, endophthalmitis, endoconditis, meningitis, pneumonia, and septicemia. The likelihood of recovery from *Pseudomonas* infection is related to the severity of the patient's underlying disease process. The reported mortality for *P. aeruginosa* pneumonia is as high as 50-80%. Even with the development of newer antibiotics, resistance remains a problem necessitating combined antibiotic treatment for severe *P. aeruginosa* infections.

Alternative therapy for the management of severe *P. aeruginosa* infections have been evaluated for many years. Immunotherapy has been the alternative most extensively explored. In this area, attention has focussed on the virulence factors. As with most bacterial pathogens, virulence of *Pseudomonas aeruginosa* is multifactorial and

is the product of many interacting variables, involving both the bacterium and the host.

Evidence suggests that the initial event in infection is the adherence of microorganisms to epithelial cells of mucosal surfaces [E.H. Blackey, J. Infect. Dis., 143: 325-345 (1981)]. Organisms that are unable to adhere to mucosal surfaces fail to colonize because they are removed by the secretions that bathe the mucosal surfaces. The adherence process is dependent upon the specific recognition between bacteria and epithelial cells. For a number of gram-negative bacteria, including P. aeruginosa, attention has been directed to surface appendages as mediations of adherence. These surface appendages are termed 'adhesins', and the distribution of specific receptors for adhesins determines many of the tissue tropisms noted for bacteria. In the case of P. aeruginosa, polar pili present on the surface of the organism have been shown to mediate adherence to buccal epithelial cells. The evidence for this is as follows: (1) nonpiliated strains do not adhere to epithelial cells; (2) protease treatment of P. aeruginosa drastically reduces the ability of these organisms to adhere to epithelial cells; (3) preincubation of epithelial cells with purified pili significantly decreases the adherence of intact organisms, and (4) antibody to purified pili prevents the adherence of organisms to buccal epithelial cells.

Although P. aeruginosa pili are antigenically heterogeneous in different clinical isolates, there is evidence that a portion of the pilus is conserved [see Paranchych et al., Antibiotics Chemother. 36: 49-57 (1985)]. As this common domain is important in binding to epithelial cells [see Doig et al., Infection and Immun., 56: 1641-1646 (1988)], it is useful in the production of a broadly effective P. aeruginosa pili vaccine.

The surface of many gram-negative bacteria, e.g., E. coli, P. aeruginosa, M. bovis, N. gonorrhea, are covered with filamentous structures called pili or fimbriae. Pili are composed primarily of protein (pilin) and have
5 been found to act as antigenic determinants when injected into test animals. Certain pili, including PAO, PAK, CD4, as they are commonly referred to, and others, mediate the colonization of P. aeruginosa in humans. Some bacterial cells lacking these pili, either through
10 mutation or loss of the plasmid carrying the pilus gene, are incapable of colonizing mucosa. Apparently, the pili on the surface of the bacterium adhere to the lining of the throat and trachea through specific interactions with epithelial cell receptors. P. aeruginosa can utilize
15 both pili and alginate (the principle component of the P. aeruginosa capsule) as adhesins to mediate attachment to human respiratory epithelial cells [see Doig et al., Infection and Immun., 55: 1517-1522 (1987); Doig et al., Infection and Immun., 56: 1641-1646 (1988); Marcus et
20 al., Infection and Immun., 47: 723-729 (1985); Ramphal et al., Infection and Immun., 44: 38-40 (1984); Ramphal et al., Infection and Immun., 47: 1-4 (1985); Woods et al., Infection and Immun., 29: 1146-1151 (1980).

Equilibrium analysis of P. aeruginosa binding to
25 human respiratory epithelial cells indicates that the Pseudomonas pilus adhesin has a considerably higher apparent affinity or binding constant (K_a) than does the alginate adhesin [McEachran et al., Can. J. Microbiol., 31: 563-569 (1985), McEachran et al., J. Microbiol. Meth., 5: 99-111 (1986); Doig et al., Infection and Immun., 55: 1517-1522 (1987)].
30

These observations suggest that the pilus adhesin is likely the dominant Pseudomonas adhesin in the initiation of an infection. Adhesin-mediated anchorage is a
35 prerequisite for the induction of disease by P. aeruginosa.

Anything which would biologically interfere with this adhesion should be effective in blocking infection. Such a technique has been investigated by monoclonal antibody treatment of bacterial adhesion and has been reported in the patent literature, e.g., U.S. patent 4,443,549 and U.S. patent 4,702,911 and published U.S. PCT application S.N. PCT/US85/00565. It is important to note that bacterial adhesins are unique so that this technique is not predictable with various other bacteria.

SUMMARY OF THE INVENTION


According to an aspect of the invention, a polypeptide is provided that is smaller than a naturally-occurring P. aeruginosa pilin protein, and the pharmaceutically acceptable salts thereof, that are capable of immunologically mimicking a conserved antigenic determinant site within a semi-variable region of the carboxy-terminal half of the P. aeruginosa pilin and thus are capable of being an antigen, or an immunogen, operable in blocking a P. aeruginosa infection. Additionally, the present invention provides a vaccine that contains such an immunogen as well as a method of immunization against a P. aeruginosa infection. This invention further contemplates a diagnostic assay utilizing a polypeptide of this invention and/or a receptor such as an antibody elicited by such a polypeptide.

According to an aspect of the invention, the pure homogeneous polypeptide comprises at least one amino acid residue sequence, containing about 12 amino acid residues and up to about 20 amino acid residues, that defines a sequence capable of immunologically mimicking an antigenic determinant site of a P. aeruginosa pilin. This amino acid residue sequence can repeat as a unit one or more times in the same poly-peptide molecule. More than one type of such repeating unit, and more than one repeating unit of the same type, can be present in a

single polypeptide molecule that embodies the present invention.

Such polypeptide can be made as a protein synthesized by genetic engineering techniques or it can be built-up from individual amino acid residues, or amino acid residue blocks.

According to a preferred aspect of the invention, pure homogeneous polypeptides embodying this invention can be defined as including the amino acid residue sequence, taken from left to right and in the direction from the amino-terminus to the carboxy-terminus, of the formula:



wherein the X designates an amino acid residue or a blank. If a blank occurs between residues X_n and X_{n+2} , where $n=1$ to 18, then X_n is connected to X_{n+2} through an amide bond (-CONH-). This amide bond results from the condensation of the α -carboxy-terminus of residue X_n with the α -amino-terminus of residue X_{n+2} .

In the above formula:

X_1 is the amino acid residue Cysteine (C);

X_2 is an amino acid residue from the group Glycine (G), Lysine (K), Serine (S) or is a blank;

X_3 is an amino acid residue from the group Alanine (A) or Isoleucine (I) or is a blank;

X_4 is an amino acid residue from the group Serine (S) or Threonine (T) or is a blank;

X_5 is an amino acid residue from the group Glycine (G), Lysine (K), Serine (S) or is a blank;

X_6 is an amino acid residue from the group Serine (S) or Threonine (T);

X_7 is an amino acid residue from the group Aspartic acid (D), Leucine (L), Asparagine (N), Proline (P) or is a blank;

X_8 is an amino acid from the group Alanine (A), Leucine (L), Valine (V) or is a blank;

X₉ is the amino acid Threonine (T) or is a blank;

X₁₀ is an amino acid from the group Alanine (A), Asparagine (N), Glutamine (Q), Trptophan (W) or is a blank;

5 X₁₁ is an amino acid residue from the group Glycine (G), Tryptophan (N) or is a blank;

X₁₂ is an amino acid residue from the group Aspartic acid (D), Glutamic acid (E), Lysine (K);

10 X₁₃ is an amino acid residue from the group Alanine (A), Glutamic acid (E), Asparagine (N), Proline (P);

X₁₄ is an amino acid residue from the group Lysine (K), Methionine (M), Asparagine (N), Glutamine (Q);

X₁₅ is an amino acid residue from the group Phenylalanine (F), Tyrosine (Y);

15 X₁₆ is an amino acid residue from the group Alanine (A), Isoleucine (I), Leucine (L), Arginine (R), Threonine (T);

X₁₇ is the amino acid residue Proline (P);

20 X₁₈ is an amino acid residue from the group Alanine (A), Lysine (K), Asparagine (N), Serine (S);

X₁₉ is an amino acid residue from the group Glycine (G), Asparagine (N), Threonine (T);

X₂₀ is the amino acid Cysteine (C).

25 Particularly preferred amino acid residue sequences within the above groupings taken from left to right, and in the direction from the amino-terminus to the carboxy-terminus, are:

30 C T S D Q D E Q F I P K G C
C K S T Q D P M F T P K G C
C T S T Q E E M F I P K G C
C T S N A D N K Y L P K T C
C A T T V D A K F R P N G C
C K I T K T P T A W K P N Y A P A N C
C G I T G S P T N W K A N Y A P A N C
35 C S I S S T P A N W K P N Y A P S N C

The description of the synthetic peptide of this patent does not represent a previously published sequence

but is a composite of the critical residues involved in binding to buccal and tracheal epithelial cell surface receptors. Several sequences have been published and are subsets of this composite sequence.

5 BRIEF DESCRIPTION OF THE DRAWINGS

Preferred embodiments of the invention are discussed with respect to the following Examples in which:

Figure 1 is a graph showing the binding of synthetic peptide Ac17red and Ac17ox to human BECs;

10 Figure 2 is a modified Lineweaver-Burk plot of the binding of synthetic peptides to human BECs;

Figure 3 is a modified Lineweaver-Burk plot of the binding of PAK pili to human BECs;

15 Figure 4 is a blot showing the binding of PAK pili and synthetic peptide to blotted BEC proteins on nitrocellulose;

Figure 5 shows micrographs A, B, C and D of indirect immunofluorescent localization of PAK pili binding to fractionated ciliated TECs;

20 Figure 6 shows micrographs A, B, C, D, E, and F of indirect immunofluorescent localization of binding of synthetic peptides to human ciliated TECs; and

Figure 7 is a bar graph demonstrating the Fab fragments produced against regions other than the C-terminal of PAK pilin and are ineffective in preventing pilin binding to BECs.

25 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Polypeptides of the present invention are smaller than the naturally-occurring *Pseudomonas aeruginosa* pilin protein and include an amino acid residue sequence of
30 about 12 to about 20 amino acid residues, preferably 12 to 20 amino acid residues, that immunologically mimic a conserved antigenic determinant site in the region of the carboxy-terminal half of *P. aeruginosa* pilin protein. As
35 such, the present polypeptides are useful by themselves, or as pharmaceutically acceptable salts, as the active constituent in a vaccine, as an inoculum, or in a

diagnostic assay. The polypeptides of this invention are prepared by a variety of synthetic techniques as will be described. Such synthetic production of the subject polypeptides result in pure materials; i.e., homogeneous peptide sequences which are substantially free of at least any foreign biological materials.

The term "antigenic determinant", as used herein, designates the structural component of a molecule that is responsible for specific interaction with corresponding antibody (immunoglobulin) molecules elicited by the same or related antigen. Antigenic determinants in the present polypeptides comprise chemically active surface groupings of amino acid residues.

The term "antigen", as used herein, means an entity that is bound by an antibody.

The term "immunogen", as used herein, describes an entity that induces antibody production in the host animal. In some instances the antigen and the immunogen are the same entity, while in other instances the two entities are different.

The phrase "immunologically mimicks" is used herein to mean that an immunogenic polypeptide of this invention is not a natural protein or a cleaved fragment of a natural protein, but a manufactured polypeptide, as by solid phase synthesis or genetic engineering techniques, which polypeptide induces production of antibodies that bind to the inducing polypeptide and also to a corresponding pilin or pilin polypeptide portion.

All amino acid residues identified herein are in the natural or L-configuration unless otherwise specified. In keeping with standard peptide nomenclature, abbreviations for amino acid residues that have been used herein are as follows:

		<u>Symbol</u>		<u>Amino Acid</u>
		1 Letter	3 Letter	
		Y	TYR	-L-tyrosine
		G	GLY	-glycine
5		F	PHE	-L-phenylalanine
		M	MET	-L-methionine
		A	ALA	-L-alanine
		S	SER	-L-serine
		I	ILE	-L-isoleucine
10		L	LEU	-L-leucine
		T	THR	-L-threonine
		V	VAL	-L-valine
		P	PRO	-L-proline
		K	LYS	-L-lysine
15		N	ASN	-L-asparagine
		H	HIS	-L-histidine
		Q	GLN	-L-glutamine
		E	GLU	-L-glutamic acid
		W	TRP	-L-tryptophan
20		R	ARG	-L-arginine
		D	ASP	-L-aspartic acid
		C	CYS	-L-cysteine

The term "pharmaceutically acceptable salts", as used herein, refers to the non-toxic salts, such as, alkali metal, alkaline earth metal and ammonium salts commonly used in the pharmaceutical industry including the sodium, potassium, lithium, calcium, magnesium, and ammonium salts and the like which are prepared by methods well known in the art. The term also includes non-toxic acid addition salts which are generally prepared by reacting the compounds of this invention with a suitable organic or inorganic acid. Representative salts include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, laureate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate and the like. The polypeptides meeting the foregoing conditions elicit

antibodies in a mammalian host and are believed to immunologically mimic a desired antigenic determinant site within a region of the carboxy-terminal half of the pilin protein.

5 One or more amino acid residue sequences meeting the foregoing conditions can be present as repeating units. Additionally, polypeptides containing one or more such amino acid residue sequences can be formed into relatively larger synthetic moieties by joining the
10 individual polypeptides head-to-tail.

These polypeptides can be characterized as those including the amino acid sequences taken from left to right in the direction from the amino-terminus to the carboxy-terminus, of the formula:

15 $-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-$
 $X_{17}-X_{18}-X_{19}-X_{20}-$

wherein the X designates an amino acid residue or a blank. If a blank occurs between residues X_n and X_{n+2} , where $n=1$ to 18, then X_n is connected to X_{n+2} through an
20 amide bond (-CONH-). This amide bond results from the condensation of the α -carboxy-terminus of residue X_n with the α -amino terminus of residue X_{n+2} .

Additionally,

X_1 is the amino acid residue Cysteine (C);
25 X_2 is an amino acid residue from the group Glycine (G), Lysine (K), Serine (S) or is a blank;
 X_3 is an amino acid residue from the group Alanine (A) or Isoleucine (I) or is a blank;
 X_4 is an amino acid residue from the group Serine (S)
30 or Threonine (T) or is a blank;
 X_5 is an amino acid residue from the group Glycine (G), Lysine (K), Serine (S) or is a blank;
 X_6 is an amino acid residue from the group Serine (S) or Threonine (T);
35 X_7 is an amino acid residue from the group Aspartic acid (D), Leucine (L), Asparagine (N), Proline (P) or is a blank;

X_8 is an amino acid from the group Alanine (A),
Leucine (L), Valine (V) or is a blank;

X_9 is an amino acid from the group Threonine (T) or
is a blank;

5 X_{10} is an amino acid from the group Alanine (A),
Asparagine (N), Glutamine (Q), Tryptophan (W) or is a
blank;

X_{11} is an amino acid residue from the group Glycine
(G), Tryptophan (N) or is a blank;

10 X_{12} is an amino acid residue from the group Aspartic
acid (D), Glutamic acid (E), Lysine (K);

X_{13} is an amino acid residue from the group Alanine
(A), Glutamic acid (E), Asparagine (N), Proline (P);

15 X_{14} is an amino acid residue from the group Lysine
(K), Methionine (M), Asparagine (N), Glutamine (Q);

X_{15} is an amino acid from the group Phenylalanine
(F), Tyrosine (Y);

20 X_{16} is an amino acid residue from the group Alanine
(A), Isoleucine (I), Leucine (L), Arginine (R), Threonine
(T);

X_{17} is the amino acid residue Proline (P);

X_{18} is an amino acid residue from the group Alanine
(A), Lysine (K), Asparagine (N), Serine (S).

25 X_{19} is an amino acid residue from the group Glycine
(G), Asparagine (N), Threonine (T).

X_{20} is the amino acid Cysteine (C).

30 Particularly preferred amino acid residue sequences
within the above groupings taken from left to right, and
in the direction from the amino-terminus to the
carboxy-terminus, are:

35 C T S D Q D E Q F I P K G C
 C K S T Q D P M F T P K G C
 C T S T Q E E M F I P K G C
 C T S N A D N K Y L P K T C
 C A T T V D A K F R P N G C
 C K I T K T P T A W K P N Y A P A N C
 C G I T G S P T N W K A N Y A P A N C

C S I S S T P A N W K P N Y A P S N C

which sequences have been found to be located in the region of the carboxy-terminus half of pilin proteins from eight different strains of P. aeruginosa as described by Pasloske et al., J. of Bacteriology, 170: 3738-3741 (1988).

Particularly preferred structures for the sequences described here are those in which these sequences contain intramolecular disulfide bonds. These disulfide bonds occur through oxidative coupling of the sulphur atoms of the two Cysteine (c) residues contained in each sequence.

In a typical laboratory preparation, 10 milligrams of the di-CYS-polypeptide (containing amino- and carboxy-terminal cysteine residues in unoxidized form) are dissolved in 250 milliliters of 0.1 molar ammonium bicarbonate buffer having a pH value of about 8. The dissolved di-CYS-polypeptide is then air oxidized by stirring the resulting solution gently for a period of about 18 hours, or until there is no detectable free mercaptan by the Ellman test. [See, Ellman, Arch. Biochem. Biophys. 82: 70-77 (1959)]. The cyclized peptide so prepared is then typically isolated by freeze drying, redissolution and chromatographic purification.

These preferred sequences have been found to be conserved within the region of the carboxy-terminal half of pilin proteins from eight different strains of P. aeruginosa as described by Pasloske et al., J. Bacteriology 170: 3738-3741 (1988) as well as antigenically related variants thereof as defined herein below.

More than one of the foregoing sequences can be present in the same polypeptide, usually spaced from one another by a chain of other amino acid residues or other suitable linking group.

Biochemical evidence from immunoassay and from analogy with conserved protein-protein interaction in solved X-ray crystallographic structures with differing

sequences such as in the dimer contacts of oligomeric enzymes, indicates that the conservation of protein-protein recognition does not require a strict conservation of sequence, for relatedness. While single amino acid residue changes may affect such recognition to a wide degree depending upon the nature of the substitution, in general terms, the relatedness of two differing amino acid sequences with respect to protein-protein (and antigenic and/or immunogenic) recognition can be expressed in terms of seven basic amino acid parameters:

- (1) hydrophobicity;
- (2) polarity;
- (3) size of side chain;
- (4) charge;
- (5) preference for turned secondary structure;
- (6) preference for beta strand secondary structure;

and

(7) preference for helical secondary structure.

To define the degree of sequence identity relevant to antigenic and/or immunogenic recognition, and thus antigenically related variants, the following classification using empirical similarities between amino acid residues can be used. This classification is based on an arrangement of amino acid residues which reveals exchange groups. Amino acids within such a group exchange preferentially with each other. Therefore, they resemble each other most with respect to their overall impact on protein structures. These empirical similarities are outlined in "Principles of Protein Structure", Charles R. Cantow, Editor, Springer-Verlag, New York, Inc. 1979, page 14 and are as follows:

	<u>Exchange Group</u>	<u>Description</u>
	1	The aromatics Phe (F), Tyr (Y) and Tryptophan (W);
5	2	The positively charged residues Lys (K), Arg (R) and His (H);
	3	The large aliphatic nonpolar residues Val (V), Leu (L), Ile (I), Met (M) and Cys (C);
10	4	The small residues Ser (S), Thr (T), Asp (D), Asn (N), Gly (G), Ala (A), Glu (E), Gln (Q) and Pro (P).
For the purpose of this invention a related peptide is defined in the following way:		
15	As any peptide containing a Cysteine residue (C) at position X_1 followed by,	
	- an amino acid residue from groups 2 or 4 in position X_2 or a blank.	
	- an amino acid residue from groups 3 or 4 in position X_3 or a blank.	
20	- an amino acid residue from group 4 in position X_4 or a blank.	
	- an amino acid residue from groups 2 or 4 in position X_5 or a blank.	
25	- an amino acid residue from group 4 in position X_6 or a blank.	
	- an amino acid residue from groups 3 or 4 in position X_7 or a blank.	
	- an amino acid residue from groups 3 or 4 in position X_8 or a blank.	
30	- an amino acid residue from group 4 in position X_9 or a blank.	
	- an amino acid residue from group 4 in position X_{10} or a blank.	
	- an amino acid residue from groups 1 or 4 in position X_{11} or a blank.	
35	- an amino acid residue from groups 2 or 4 in position X_{12} .	

- an amino acid residue from group 4 in position X_{13} .
- an amino acid residue from groups 2, 3 or 4 in position X_{14} .
- 5 - an amino acid residue from group 1 in position X_{15} .
- an amino acid residue from groups 2, 3 or 4 in position X_{16} .
- an amino acid residue from group 4 in position X_{17} .
- 10 - an amino acid residue from groups 2 or 4 in position X_{18} .
- an amino acid residue from group 4 in position X_{19} .
- 15 and containing a Cysteine residue (c) at position X_{20} .

The peptides, according to this invention and used herein, are preferably coupled to higher molecular weight compounds. For example, proteins such as keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA) or toxoid proteins can be used in the following method.

Peptide conjugation to protein carriers.

The peptides were conjugated to keyhole limpet hemocyanin (KLH) or bovine serum albumin BSA via a linker consisting of a [^{14}C] glycine and a benzophenone cross-linking group (benzoyl benzoic acid), which was added to the peptide during synthesis while the peptide was still on a solid matrix. The hapten was first dissolved in 10-20 μl water in a test tube. The protein carriers (10 mg/100 μl) were then added and mixed. Covalent attachment of the peptide to the carrier occurs following activation of the benzoylbenzoyl group by UV irradiation at 4°C for an hour in a RPR 208 preparative reactor equipped with RPR 3500 Å lamps. Unconjugated haptens were removed by successive dialysis against 8 M urea, 100 mM and 25 mM ammonium bicarbonate. The product was freeze-dried and the peptide incorporation determined

by measuring the radioactivity incorporated per mole carrier. Peptide/protein ratios of about 4:1 and 10:1 were obtained for the oxidized and reduced peptides, respectively.

5 A mixture of the foregoing polypeptides, including those having antigenically-related regions as defined herein above, can also be used to make up a vaccine against or a diagnostic assay for a P. aeruginosa infection, and/or an inoculum for raising antibodies.
10 It is also understood that anti-idiotypic antibodies can be developed as vaccines based on the sequence of this invention. Such technique is described in more detail in Kennedy et al, Vaccines 86 "New Approaches to Immunization", Cold Spring Harbour, 1986, p. 85.

15 Any interference with bacterial adhesion and subsequent colonization will prevent infection. Monoclonal antibodies specific for a portion of the amino acid sequence of the P. aeruginosa pili protein can interact with the adhesins and interfere with cell
20 anchorage. Alternatively, a peptide or portion of the whole pilin amino acid sequence can be used as an immunogen to develop host antibodies which would, in turn, act to prevent bacterial anchorage and subsequent colonization. These methods, therefore, represent new
25 and useful biological agents for the prevention and treatment of P. aeruginosa disease in humans. It should be noted that this synthetic vaccine is not directed at the dominant immunogenic or antigenic site on P. aeruginosa but rather to the adhesin binding site
30 responsible for attachment of the bacterium to the surfaces of human buccal and tracheal epithelial cells. Vaccines containing effective amounts of the present polypeptides induce production of antibodies in a sufficient amount to protect the vaccinated individual
35 from infection with P. aeruginosa. Booster injections can be given if needed.

is disclosed in more detail by Gerald Quinnan,
"Proceedings of a Workshop", November 13-14, 1984
Elsevier, p. 27.

5 The synthesis by recombinant DNA techniques,
vaccination by use of a vector for vaccine antigens and
other forms and requirements for DNA expression of the
subject polypeptide are based on the use of a DNA
sequence and its analogs encoding for the desired subject
polypeptide. As one skilled in the art fully
10 appreciates, the DNA sequences encoding for polypeptides
of this invention can be readily determined by such
skilled people and expressed either *in vitro* or *in vivo* by a
suitable expression system to produce the desired
polypeptide.

15 For purposes of synthesis of the desired
polypeptide, the standard expression of the selected DNA
sequence in a suitable microorganism host is expedient.
One skilled in the art wanting to produce a desired
polypeptide sequence of this invention, can readily
20 determine and select the necessary DNA sequence which
encodes for the desired polypeptide sequence. The
selected DNA sequence is inserted in a suitable vector
for expression in a compatible host microorganism to
produce in commercial quantity the desired polypeptide.

25 The subject DNA sequence can be manipulated in
studies to understand the expression of the gene and its
product, and, to achieve production of large quantities
of the polypeptide for functional analysis, antibody
production, and patient therapy. The changes in the
30 sequence may or may not alter the expression pattern in
terms of relative quantities, tissue-specificity and
functional properties. The partial or full-length DNA
sequences, which encode for the subject protein,
unmodified or modified, may be ligated to bacterial
35 expression vectors such as the pRIT (Nilsson et al. EMBO
J. 4: 1075-1080 (1985)), pGEX (Smith and Johnson, Gene
67: 31-40 (1988)) or pATH (Spindler et al. J. Virol. 49:

Thus, the word "vaccine" in its various grammatical forms is used herein in relation to the protection of a host mammal. The word "inoculum" in its various grammatical forms is used herein to describe a composition containing a polypeptide of this invention as an active ingredient used for the preparation of antibodies that immunologically bind to P. aeruginosa pili. A vaccine and an inoculum may thus contain the identical ingredients, but their uses are different.

The polypeptides suitable as antigens or immunogens, or both, for the present purposes can be produced synthetically or by genetic engineering techniques, and can be in monomeric as well as multimeric forms for use in vaccines, inocula, or as diagnostics. When used in a vaccine or inoculum, the polypeptide may be used alone, as in the case of an oligomer or a multimer, or used linked to another carrier moiety as a conjugate. When used alone as an immunogen, a polypeptide of this invention typically contains from about 12 to about 20 amino acid residues. Such polypeptides are preferably linked to a carrier. The polypeptides of this invention are therefore pure and homogeneous without any extraneous matter as would be experienced if the polypeptides were isolated from naturally occurring polypeptides.

Particularly useful conjugate carriers include keyhole limpet hemocyanin (KLH), tetanus toxoid, poly-L-(LYS:GLU), peanut agglutinin, poly-D-Lysine, diphtheria toxoid, ovalbumin, soybean agglutinin, bovine serum albumin (BSA), human serum albumin, and the like.

The term "manufactured" as used herein means that the polypeptide molecule or polypeptide repeating unit has been built up synthetically by chemical means, i.e., chemically synthesized or by human-mediated biological means, e.g., by genetic engineering techniques, which include recombinant DNA techniques and vaccinia viruses as vectors for vaccine antigens. Such latter technique

132-141 (1984)) plasmids which can be introduced into E. coli cells for production of the corresponding polypeptides which may be isolated in accordance with the standard protein purification procedures. The DNA
5 sequence can also be transferred from its existing context to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal virus, yeast artificial chromosomes (YAC) (Burke et al. Science 236: 806-812, (1987)), somatic cells, and other simple or
10 complex organisms, such as bacteria, fungi (Timberlake and Marshall, Science 244: 1313-1317 (1989)), invertebrates, plants (Gasser and Fraley, Science 244: 1293 (1989), and pigs (Pursel et al. Science 244: 1281-1288 (1989)).

15 For expression in mammalian cells, the DNA sequence may be ligated to heterologous promoters, such as the simian virus (SV) 40, promoter in the pSV2 vector [Mulligan and Berg, Proc. Natl. Acad. Sci USA, 78:2072-2076 (1981)] and introduced into cells, such as monkey
20 COS-1 cells [Gluzman, Cell, 23:175-182 (1981)], to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin [Southern and Berg, J. Mol. Appln. Genet. 1:327-341 (1982)] and mycophenolic acid [Mulligan
25 and Berg, supra].

DNA sequences can be manipulated with standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension
30 by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-alteration via single-stranded bacteriophage intermediate.

The DNA sequence is introduced into eukaryotic
35 expression vectors by conventional techniques. These vectors are designed to permit the transcription of the DNA in eukaryotic cells by providing regulatory sequences

that initiate and enhance the transcription of the DNA and ensure its proper splicing and polyadenylation. Vectors containing the promoter and enhancer regions of the simian virus (SV)40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV 40 are readily available [Mulligan et al Proc. Natl. Acad. Sci. USA 78:1078-2076, (1981); Gorman et al Proc Natl. Acad. Sci USA 79: 6777-6781 (1982)]. The level of expression of the DNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express DNA at high levels in S. frugiperda cells [M. D. Summers and G. E. Smith in, Genetically Altered Viruses and the Environment (B. Fields, et al, eds.) vol. 22 no 319-328, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York, 1985] or by using vectors that contain promoters amenable to modulation, for example the glucocorticoid-responsive promoter from the mouse mammary tumor virus [Lee et al, Nature 294:228 (1982)]. The expression of the DNA can be monitored in the recipient cells 24 to 72 hours after introduction (transient expression).

In addition, some vectors contain selectable markers [such as the gpt [Mulligan et Berg supra] or neo [Southern and Berg J. Mol. Appln. Genet 1:327-341 (1982)] bacterial genes that permit isolation of cells, by chemical selection, that have stable, long term expression of the vectors (and therefore the DNA) in the recipient cell. The vectors can be maintained in the cells as episomal, freely replicating entities by using regulatory elements of viruses such as papilloma [Sarver et al Mol. Cell Biol. 1:486 (1981)] or Epstein-Barr [Sugden et al Mol. Cell Biol. 5:410 (1985)]. Alternatively, one can also produce cell lines that have integrated the vector into genomic DNA. Both of these types of cell lines produce the gene product on a continuous basis. One can also produce cell lines that

have amplified the number of copies of the vector (and therefore of the DNA as well) to create cell lines that can produce high levels of the polypeptide [Alt et al. J. Biol. Chem. 253: 1357 (1978)].

5 The transfer of DNA into eukaryotic, in particular human or other mammalian cells is now a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate [Graham and vander
10 Eb, Virology 52:466 (1973) or strontium phosphate [Brash et al Mol. Cell Biol. 7:2013 (1987)], electroporation [Neumann et al EMBO J 1:841 (1982)], lipofection [Felgner et al Proc Natl. Acad. Sci USA 84:7413 (1987)], DEAE dextran [McCuthan et al J. Natl Cancer Inst. 41:351
15 1968)], microinjection [Mueller et al Cell 15:579 1978)], protoplast fusion [Schafner, Proc Natl. Aca. Sci USA 72:2163] or pellet guns [Klein et al, Nature 327: 70 (1987)]. Alternatively, the DNA can be introduced by infection with virus vectors. Systems are developed that
20 use, for example, retroviruses [Bernstein et al. Genetic Engineering 7: 235, (1985)], adenoviruses [Ahmad et al J. Virol 57:267 (1986)] or Herpes virus [Spaete et al Cell 30:295 (1982)].

25 The recombinant cloning vector, according to this invention, then comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host. The DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that the polypeptide can be expressed. The
30 expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be specifically selected from the group
35 consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat

protein, the early and late promoters of SV40, promoters
derived from polyoma, adenovirus, retrovirus, baculovirus
and simian virus, the promoter for 3-phosphoglycerate
kinase, the promoters of yeast acid phosphatase, the
5 promoter of the yeast alpha-mating factors and
combinations thereof.

The host cell, which may be transfected with the
vector of this invention, may be selected from the group
consisting of E. coli, Pseudomonas, Bacillus subtilis,
10 Bacillus stearothermophilus or other bacilli; other
bacteria; yeast; fungi; insect; mouse or other animal;
or plant hosts; or human tissue cells.

Although the DNA sequences and corresponding RNA
sequences which encode for the various polypeptides of
15 this invention can be readily listed by those skilled in
the art, for purposes of reference the DNA sequences for
the preferred polypeptide sequences are as follows in
accordance with standard nomenclature where the
polypeptide sequence is identified by two sets of
20 nomenclature in the first and second view of each
preferred sequence and the corresponding DNA sequence is
set out in the third row.

	C	T	S	D	Q	D	E	Q	F	I	P	K	G	C
i) PAK	Cys Thr Ser Asp Gln Asp GAT GAG	ACC AGT GAT CAG	AGT GAT CAG	Asp Gln Asp GAT GAG	Gln Gln Asp GAT GAG	Asp Gln Asp GAT GAG	Glu Gln Asp GAT GAG	Gln Gln Asp GAT GAG	Phe Phe Ile ATT	Ile Ile Ile ATT	Pro Lys Gly Cys	Pro Lys Gly Cys	Gly Cys	TGC
ii) PAO	Cys Lys Ser Thr Gln Asp Pro Met	TCT ACC CAG CAG	TCT ACC CAG	Thr Gln Asp Pro Met	Thr Gln Asp Pro Met	Thr Gln Asp Pro Met	Thr Gln Asp Pro Met	Thr Gln Asp Pro Met	Phe Phe Thr TTT	Thr Thr Thr TTT	Pro Lys Gly Cys	Pro Lys Gly Cys	Gly Cys	TGT
iii) CD ₆	Cys Thr Ser Thr Gln Glu Met	TCT ACT CAG CAG	TCT ACT CAG	Thr Gln Glu Met	Thr Gln Glu Met	Thr Gln Glu Met	Thr Gln Glu Met	Thr Gln Glu Met	Phe Phe Ile TTT	Ile Ile Ile TTT	Pro Lys Gly Cys	Pro Lys Gly Cys	Gly Cys	TGT
iv) K ₁₂₂	Cys Thr Ser Asn Ala Asp Ans	TCC ACC GCA GAT AAC	TCC ACC GCA	Thr Gln Glu Met	Thr Gln Glu Met	Thr Gln Glu Met	Thr Gln Glu Met	Thr Gln Glu Met	Tyr Tyr Leu CTG	Leu Leu Leu CTG	Pro Lys Thr Cys	Pro Lys Thr Cys	Thr Cys	TGC
v) KB ₇	Cys Ala Thr Thr Val Asp Ala	GCT ACC GAT GAT GCT	GCT ACC GAT	Thr Val Asp Ala	Thr Val Asp Ala	Thr Val Asp Ala	Thr Val Asp Ala	Thr Val Asp Ala	Phe Phe Arg TTT	Arg Arg Arg TTT	Pro Asn Gly Cys	Pro Asn Gly Cys	Gly Cys	TGT
vi) P ₁	Cys Lys Ile Thr Lys Thr Pro	ACC ACC AAA ACT CCT	ACC ACC AAA	Thr Lys Thr Pro	Thr Lys Thr Pro	Thr Lys Thr Pro	Thr Lys Thr Pro	Thr Lys Thr Pro	Ala Ala Trp TGG	Ala Ala Trp TGG	Pro Lys Thr Cys	Pro Lys Thr Cys	Thr Cys	TGC
vii) 492 _c	Cys Gly Ile Thr Gly Ser Pro	ATC ATC ACT GGT TCG	ATC ATC ACT	Ile Thr Gly Ser	Ile Thr Gly Ser	Ile Thr Gly Ser	Ile Thr Gly Ser	Ile Thr Gly Ser	Ala Ala Trp TGG	Ala Ala Trp TGG	Pro Lys Thr Cys	Pro Lys Thr Cys	Thr Cys	TGC
viii) TBOU-1	Lys Ser Ile Ser Ser Thr	TCG ATC AGT AGC ACT	TCG ATC AGT	Ser Ser Ser Thr	Ser Ser Ser Thr	Ser Ser Ser Thr	Ser Ser Ser Thr	Ser Ser Ser Thr	Ala Ala Trp TGG	Ala Ala Trp TGG	Pro Lys Thr Cys	Pro Lys Thr Cys	Thr Cys	TGC

SUBSTITUTE SHEET

Several of these sequences have been published in prior literature on the investigation of the entire pilin peptide such as in Brittain, L. et al "Cloning and Sequencing of the *Pseudomonas aeruginosa* PAK Pilin Gene", FEBS 2489, Vol. 183, No. 2, pp 408-412 (1985); Parimi, Sastry A. et al, "Comparative Studies of the Amino Acid and Nucleotide Sequences of Pilin Derived from *Pseudomonas aeruginosa* PAK and PAO, Journal of Bacteriology, 164:571-577 (1985); Brittain L. et al, "Serial Isolates of *Pseudomonas aeruginosa* from a Cystic Fibrosis Patient Have Identical Pilin Sequences", Infection and Immunity, 56:665-672 (1988) and Brittain, L. et al, "Notes. Two Unusual Pilin Sequences from Different Isolates of *Pseudomonas aeruginosa*: Journal of Bacteriology 170:3738-3741 (1988).

In accordance with the previous discussion on the possible variation in the conservation of amino acid sequences, many amino acid residue substitutions may be made as previously described. Accordingly, the corresponding changes in the DNA sequence are made to encode for the desired polypeptide of this invention. Furthermore, appropriate multiples of the desired polypeptide sequences with or without linking alternate amino acid sequences may be expressed by the corresponding multiple of the DNA sequence encoding for the desired polypeptide and DNA sequence encoding for the alternate sequences.

Rather than developing a vaccine based on the produced polypeptide, it is possible to express *in vivo* in the human or animal to be protected, the vaccine antigen. This may be accomplished in accordance with the technique described in the aforementioned Quinmann "Proceedings of a Workshop" supra for expressing in the patient the desired vaccine antigen of this invention in a viral vector. In accordance with the technique described in the reference, the selected DNA sequence encoding for the desired vaccine antigen of this invention is incorporated

into the viral vector for the vaccinia virus and the patient infected by repeated injections of the constructed vaccinia virus.

Alternatively the vaccine virus may be expressed in
5 the human or animal patient by expression of the DNA in a compatible bacterial plasmid or phage. This technique for incorporating the vaccine antigen in the bacteria is discussed in depth in S.N. Chatfield et al, "Live
10 Salmonella as Vaccines and Carriers of Foreign Antigenic Determinants" Vaccines 7:495-498 (1989). For a more general discussion of the use of attenuated bacteria to produce in the patient the desired vaccine antigen, reference is made to Dougan et al, "Live Bacterial
15 Vaccines and Their Application as Carriers for Foreign Antigens", *Advances in Veterinary Science and Comparative Medicine*, Vol 33.

As with the vaccinia virus technique, the oral bacterial vaccination route uses the DNA sequence encoding for the desired vaccine antigen of this
20 invention in the patient. Accordingly, the selected DNA sequence is constructed in a suitable vector such as a plasmid compatible with the host microorganism. The microorganism is cultured to replicate the selected DNA sequence in multiple copies of the plasmid. The
25 microorganism is removed from the culture and prepared for oral administration to the patient. Upon oral administration, the microorganism reproduces and releases into the patient's system the desired vaccine antigen to which the patient has an effective immune response.
30 Accordingly, this invention contemplates the use of DNA sequences and their analogues for expression in a suitable vehicle such as a virus or bacteria, which has infected the patient to release into the patient the desired corresponding vaccine antigen of this invention.
35 Thus, the manufactured polypeptides embodying the present invention are free from naturally occurring proteins and fragments thereof. The well-known solid

phase chemical synthesis in which blocked amino acid residues are added in a serial manner to obtain the desired polypeptide is the preferred method of synthesis, and is discussed in greater detail herein below.

5 As mentioned herein above, polypeptides suitable for the purposes of the present invention can be synthesized by the well-known solid phase method. See, for example, Merrifield, J. Am. Chem. Soc. 85: 2149-2154 (1963),
10 Houghten et al., Int. J. Pept. Proc. Res. 16: 311-320 (1980) and Parker and Hodges, J. Prot. Chem. 3: 465-478 (1985), for a complete discussion of these techniques. The solid phase method of polypeptide synthesis can be practiced utilizing a Beckman Model 990B Peptide
15 Synthesizer, available commercially from Beckman Instruments Co., Berkeley, CA., U.S.A.

In preparing a synthetic polypeptide of this invention by the above solid phase method, the amino acid residues are linked to a resin (solid phase) through an amide linkage from the carboxy-terminal residue.

20 The alpha-amino group of each added amino acid typically is protected by a tertiary-butoxy-carbonyl (t-Boc) group prior to the amino acid being added into the growing polypeptide chain. The t-Boc group is then removed prior to addition of the next amino acid to the
25 growing polypeptide chain. Reactive amino acid side chains are also protected during synthesis of the polypeptide. Usual side-chain protecting groups used for the remaining amino acid residues are as follows:
30 O-(p-bromobenzyloxycarbonyl) for tyrosine, O-benzyl for threonine, serine, aspartic acid and glutamic acid, and S-methoxy-benzyl for cysteine, 2-chlorobenzyloxycarbonyl lysine and formyl tryptophane. Protected amino acids are recrystallized from appropriate solvents to give single
35 spots by thin layer chromatography. Couplings are typically carried out using a 2-fold molar excess of both protected amino acid and dicyclohexyl carbodiimide over the number of milli-equivalents of initial N-terminal

amino acid. For asparagine and glutamine, an equal molar amount of N-hydroxy-benzotriazole is added to the protected amino acid and dimethyl-formamide is used as the solvent. All coupling reactions are typically more
5 than 99% complete by the picric acid test of Gisin, Anal. Chem. Acta, 58: 248-249 (1972), or the ninhydrin test, Sarin et al., Anal. Biochem. 117: 147-157 (1981).

A portion of the resulting, protected, resin-bonded polypeptide (1 gram) is treated with two milliliters of
10 anisole, and anhydrous hydrogen fluoride, 20 milliliters, is condensed into the reaction vessel at dry ice temperature. The resulting mixture is stirred at 4° for 1.0 hour to cleave the protecting groups and remove the polypeptide from the resin. After evaporating the
15 hydrogen fluoride at a temperature of 4°C with a stream of N₂, the residue is extracted with anhydrous diethyl ether three times to remove the anisole, and the residue is dried in vacuo.

The vacuum dried material is extracted with neat
20 trifluoro acetic acid (3 times 10 milliliters each). The extraction separates the free polypeptide from the resin. After dilution with water to a concentration of 10-20% acetic acid, the resulting solution is lyophilized to provide a monomeric, unoxidized, polypeptide. The
25 peptide released from the resin is then purified by known standard chromatographic procedures and then oxidized to give the monomeric intramolecular cyclized product.

In a typical laboratory preparation, 10 milligrams of the di-Cys polypeptide (containing amino- and
30 carboxy-terminal cysteine residues in unoxidized form) are dissolved in 250 milliliters of 0.1 molar ammonium bicarbonate buffer having a pH value of about 8. The dissolved di-Cys poly-peptide is then air oxidized by stirring the resulting solution gently for a period of
35 about 18 hours, or until there is no detectable free mercaptan by the Ellman test [see, Elman, Arch. Biochem. Biophys. 82: 70-77 (1959)].

This cyclic oxidized peptide can also be polymerized from head-to-tail using the following procedure in which the cyclic polypeptide is dissolved in dimethylformamide (1 mg/mL) and benzotiazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (1.1 molar equivalents) and diisopropylethylamine (100 μ L) are added and allowed to react at room temperature for about eight hours. The polymeric peptides produced in this fashion are isolated by evaporation of the solvents and chromatographic separation. Benzyl protecting groups are then removed by treatment of the polymer with anisole and anhydrous hydrogen fluoride at -10°C for 110 hour. After removal of the hydrogen fluoride at -10°C with a stream of N_2 the residue is extracted with anhydrous diethyl ether three times to remove the anisole and the residue. Polypeptide multimers containing oxidized cyclic monomeric units may be used for the preparation of vaccine against Pseudomonas aeruginosa. In this event the method of synthesis must follow the known solid-phase method developed by Atherton et al., J.C.S. Perkin 1: 538-546 (1981), which disclosures are incorporated herein by reference. This method can be practiced utilizing an LKB BioLynx model 4175 peptide synthesizer available commercially from LKB Biochrom, Ltd., Cambridge, England.

In preparing a synthetic polypeptide of this invention by the above solid-phase method, the amino acid residues are linked to a resin (solid-phase) through an ester linkage from the carboxy-terminal residue.

The alpha-amino group of each added amino acid typically is protected by a 9-fluorenyl-methoxycarbonyl (Fmoc) group prior to the amino acid being added onto the growing polypeptide chain. The Fmoc group is then removed prior to addition of the next amino acid to the growing polypeptide chain. Reactive amino acid side chains are also protected during synthesis of the polypeptide. Usual side-chain protecting groups used for the remaining amino acid residues are as follows:

o-(p-bromobenzoyloxycarbonyl) for tyrosine, o-benzyl for threonine and serine, -phenacyl for aspartic and benzyl for glutamic acid, S-tert-butyl for cysteine and 2-chlorobenzoyloxy-carbonyl for lysine. Couplings are typically carried out using a 2-fold molar excess of protected amino acid and one equivalent of dicyclohexyl carbodiimide over the number of milliequivalents of initial N-terminal amino acid. For asparagine (N) and glutamine (Q), 2 molar equivalents of N-hydroxy-benzotriazole and dicyclohexyl carbodiimide are used. All coupling reactions are typically monitored by the ninhydrin test of Sarin, Anal. Biochem. 117: 147-157 (1981) and are typically more than 99% complete.

A portion of this resin is cleaved to release peptide for oxidation and polymerization. Cleavage to release partially deprotected peptide is accomplished using the following method which utilized 95% trifluoroacetic acid (5 mL/50 mg resin). The resin (50 mg) is suspended in 95% trifluoroacetic acid containing anisole (3%), ethanedithiol (1%) and ethylmethyl sulphide (1%) by volume and the reaction is allowed to proceed at room temperature for 2-3 hours. The resin is filtered to remove the peptide and scavengers and the resin is washed with neat trifluoroacetic acid (3-5 mL). The combined filtrates are evaporated under vacuum and the residue triturated with diethyl ether. Finally the residue is dissolved in 0.5% trifluoroacetic acid in water and lyophilized.

This crude peptide can be purified by known reversed-phase HPLC methods and the purified peptide cyclized by air oxidation in 0.1 molar ammonium bicarbonate buffer having a pH value of about 8 for a period of about 18 hours as described hereinabove. Isolation of the cyclized product from the oxidation procedure follows known chromatographic techniques. Synthesis of the polymeric polypeptide is performed by head-to-tail coupling of the free amino and

carboxy-termini using benzotriazol-1-yloxytris (dimethyl amino) phosphonium hexafluorophosphate (1.1 molar equivalent) and diisopropyl ethylamine (100 l) at room temperature for about 8 hours. Purification of the multimers is then accomplished using known size-exclusion chromatographic techniques. Cleavage of the remaining benzyl side chain protecting groups is carried out by treatment of the multimers with anhydrous hydrogen fluoride (9 ml) containing anisole (1 mL) for about 1 hour at about -10°C. Isolation of the deprotected multimers is performed by evaporation of the hydrogen fluoride under a stream of N₂ gas while maintaining the temperature at about -10°C. The product is then triturated with diethyl ether to remove the scavenger and dissolved in aqueous 0.5% trifluoroacetic acid and lyophilized.

Alternatively, if the sequence contains benzyl protected serine and threonine in combination with tert-butyl cysteine, then cleavage before cyclization may be carried out in liquid anhydrous hydrogen fluoride (9 mL) containing anisole (1 mL) and ethandithiol (25 µL). Subsequent to this cleavage, cyclization and polymerization will provide the multimeric polypeptide. Purification at each step in the synthesis is accomplished utilizing chromatographic techniques known in the art.

Alternatively, purified cyclic polypeptide obtained by the methods described hereinabove may be attached directly to a core matrix called the multiple antigen peptide system (MAP) known in the art and described by J.P. Tam, Proc. Natl. Acad. Sci. U.S.A. 85: 5409-5413 (1988). Attachment of cyclic monomeric polypeptide is performed using an 8:1 molar ratio of polypeptide to core matrix in dimethylformamide containing 8 equivalents of benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate and diisopropylethylamine (100 µL).

Vaccines and inocula of the present invention may be administered by injection, usually intramuscularly or subcutaneously, orally by means of an enteric capsule or tablet, as a suppository, as a nasal spray, and by other
5 suitable routes of administration. For a human patient, a suitable dose of the polypeptide depends, in part, upon the chosen route of administration and a number of other factors. Included among those factors are the body weight of the mammal to be immunized, the carrier when
10 used, the adjuvant when used, and the number of inoculations desired to be used.

Individual inoculations for a human patient typically contain unit doses of about 10 micrograms to about 100 milligrams of polypeptide, exclusive of any
15 carrier to which the polypeptide may be linked. If desired, a series of doses may be administered over a period of time for optimum immunity. Unit dosage forms of the vaccine can also be provided, if desired, containing the aforementioned amounts of the polypeptide.

20 In any event, the immunogen contained in a vaccine or an inoculum is present in an "effective amount", which amount depends upon a variety of factors as is well known in the immunological arts, e.g., the body weight of the mammal to be immunized, the carrier moiety used, the
25 adjuvant used, the duration of protection sought, and the desired immunization protocol.

Whole antibodies, as well as substantially whole antibodies, raised to the polypeptides of this invention and antibody combining sites prepared from such
30 antibodies constitute still another aspect of this invention. These molecules are collectively referred to as receptors.

Receptors are raised in mammals such as rabbits, goats, horses and the like by immunization using the
35 inocula described hereinbefore. Immunization procedures are substantially the same as those used in vaccinations except that powerful adjuvants, such as Complete Freund's

Adjuvant (CFA) and/or Incomplete Freund's Adjuvant (IFA) as they are commonly known, that are not acceptable for human use can be included in animal inocula.

Typical inoculum stock solutions are prepared with CFA, IFA or alum as follows: An amount of the polypeptide, synthetic polypeptide-conjugate or polymeric polypeptide sufficient to provide the desired, effective amount of polypeptide per inoculation is dissolved in PBS at a pH value of 7.2. Equal volumes of CFA or IFA are then mixed with the polypeptide solution to provide an inoculum containing polypeptide, water and adjuvant in which the water-to-oil ratio is about 1:1. The mixture is thereafter homogenized to provide the inoculum stock solution. When alum is used, about 200 micrograms of conjugate is absorbed onto about 4 milligrams of alum to prepare the stock inoculum.

Rabbits can be utilized herein to raise antipolypeptide antibodies. When so used, the host rabbit is typically injected subcutaneously with an inoculum comprising 200 micrograms of a polypeptide conjugate (polypeptide plus carrier) emulsified in CFA; 200 micrograms of polypeptide conjugate in IFA; and 200 micrograms of polypeptide conjugate with 4 milligrams alum injected intraperitoneally on days 0, 14 and 21, respectively, of the immunization schedule. Each inoculation (immunization) consists of four injections of the inoculum. Mice may be immunized in a similar way using about one tenth of the above dose per injection.

Animals are typically bled 4 and 15 weeks after the first injection. Control pre-immune serum is obtained from each animal by bleeding just before the initial immunization.

Control inoculum stock solutions can also be prepared with keyhole limpet hemocyanin (KLH), KLH in CFA or IFA, KLH-alum absorbed, KLH-alum absorbed-

pertussis, edestin, thyroglobulin, tetanus toxoid, tetanus toxoid in IFA, cholera toxoid and cholera toxoid in IFA, and the like.

5 The efficacy of the above immunization procedure is typically determined by means of an ELISA in which the immunogenic polypeptide of this invention is used as the antigen to determine the amount of antibodies present in diluted sera obtained from the above bleeds. Sera that provide anti-polypeptide antibody titers (dilutions) of
10 at least about 1:160 are considered useful in providing the antibodies of this invention. The typically utilized ELISA test is described in greater detail in Bittle et al., Nature 298, 30-33 (1982).

Suitable monoclonal receptors, typically whole
15 antibodies, may also be prepared using hybridoma technology as described by Niman et al., Proc. Natl. Acad. Sci. USA 80: 4949-4953 (1983). Monoclonal receptors need not only be obtained from hybridoma supernatants, but may also be obtained in generally large
20 quantities from ascites fluid of mammals into which the desired hybridoma has been introduced. Production of monoclonal antibodies using ascites fluid is well known and will not be dealt with further herein. A receptor of this invention binds both to the polypeptide to which
25 it was raised and also to the corresponding pilin protein whose antigenic determinant site the polypeptide of this invention immunologically mimicks. Thus, a polypeptide of this invention may be both an immunogen and an antigen.

30 The receptors of this invention are a subset of the naturally occurring polyclonal antibodies since they are raised to an immunogen which mimics a small fragment of an intact pilin molecule. Consequently, receptors of this invention bind to epitopes of the polypeptide (which
35 is a part of the pilin molecule) while naturally occurring antibodies raised to a *Pseudomonas* pilin bind to epitopes throughout the pilin molecule.

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

The polypeptides, antibodies, and antibody combining sites provided by these polypeptides, and methods of the present invention may also be used for diagnostic tests, such as immunoassays. Such diagnostic techniques include, for example, enzyme immune assay, enzyme multiplied immunoassay technique (EMIT) enzyme-linked immunosorbent assay (ELISA), radio-immune assay (RIA), fluorescence immune assay, either single or double antibody techniques, and other techniques in which either the antibody combining site or the antigen is labeled with some detectable tag. See generally Maggio, Enzyme Immunoassay, CRC Press, Cleveland, Ohio (1981) and Goldman, M., Fluorescent Antibody Methods, Academic Press, New York, N.Y. (1980).

An illustrative diagnostic system embodying the present invention to detect P. aeruginosa contains receptor molecules such as antibodies, substantially whole antibodies, or antibody combining sites, raised to a polypeptide of this invention. The system also includes an indicating means for signaling the presence of an immunoreaction between the receptor and the antigen. The indicating means allows the immunoreaction to be detected. When mixed with a body sample such as sputum, the receptor molecule immunoreacts with the pilin antigen to form an immunoreactant, and the indicating means present then signals the immunoreaction.

One such exemplary embodiment is an immunofluorescent assay in which a sputum smear is acetone-fixed to a plain microscope slide. An aliquot of antibodies raised in accordance with this invention, e.g., raised in rabbits, generally about 10 micrograms to about 500 micrograms, is incubated on the slides using well-known techniques.

After rinsing away an unimmunoreacted antibodies and blocking non-specific binding sites on the slide with a protein such as BSA, a second antibody, such as a goat anti-rabbit antibody can then be incubated on the test

slide, if desired. The second antibody is labeled by being linked to a fluorochrome dye such as fluorescein isothiocyanate (FITC).

5 After this second incubation, any excess of the second antibody is rinsed off leaving any FITC-labeled goat anti-rabbit antibodies that bound to the first antibodies on the test slide. Presence of the FITC-labeled antibodies may be detected using fluorescent microscopy and thereby signal the presence of a
10 *Pseudomonas* infection.

The use of whole, intact, biologically active antibodies for the receptor molecules is not necessary in many diagnostic systems such as the immunofluorescent assay described above. Rather, only the immunologically
15 active, idiotype-containing, antigen binding and recognition receptor site; i.e., the antibody combining site, of the antibody molecule may be used. Examples of such antibody combining sites are those known in the art as Fab and F(ab')₂ antibody portions that are prepared by
20 methods well known in the art.

Another diagnostic method of this invention is an ELISA assay. Here, a polypeptide antigen of this invention is bound on a solid support such as the walls of a microtiter plate. Non-specific binding sites on the
25 microtiter well walls are thereafter blocked with a protein such as BSA. Unbound polypeptide and BSA are removed from the microtiter well as by rinsing.

A body sample such as that above is admixed with an excess of an antibody of this invention in an aqueous
30 solution, and the admixture is maintained for a time sufficient to form an immunoreaction between the antibody and any *Pseudomonas* pili antigen present. That liquid admixture is then mixed with the above-described polypeptide-bound solid support to form a second
35 admixture containing solid and liquid phases. The solid/liquid phase admixture is maintained for a time sufficient for previously unreacted antibodies to

immunoreact with the polypeptide antigen. The liquid phase is thereafter separated from the solid phase. A solution of a second, labeled antibody that reacts with the first-named antibody is then admixed with the solid phase. An exemplary second antibody is an alkaline-phosphatase-linked goat anti-rabbit IgG where the first-named antibodies are raised in rabbits. The admixture formed from the solid phase and the second, labeled antibody solution is maintained for a time period sufficient to form an immunoreaction between the two antibodies. The solid and liquid phases are thereafter separated.

A solution containing a substrate for the enzyme such as p-nitrophenylphosphate is thereafter admixed with the solid phase. The optical density at a preselected wave length (e.g., 405 nanometers) may then be determined after a predetermined time period has elapsed and compared to the optical density of a control to determine whether the Pseudomonas antigen was present in the body sample.

The present invention is further illustrated by the following detailed examples.

EXAMPLE 1: POLYPEPTIDE SYNTHESIS

A series of short synthetic polypeptides whose amino acid residue sequences correspond to small segments of the Pseudomonas pilin protein were synthesized according to the method of Merrifield, J. Am. Chem. Soc. 85: 2149-2154 (1963), as modified by Houghten et al., Int. J. Pept. Proc. Res. 16: 311-320 (1980), using a Beckman Model 990B Peptide Synthesizer (Beckman Instruments Co., Berkeley, CA, U.S.A.). The polypeptide designations and the location in the Pseudomonas pilin protein of the corresponding amino acid sequence is shown in Table 1, below.

TABLE 1

Synthetic Polypeptide Corresponding to

Pseudomonas Pilin Segment

	Designation ¹	Location ²	Amino Acid Residue Sequence
5	PAK 128-144	128-144	K C T S D Q D E Q F I P K G C S

1 Polypeptide coupled to KLH or BSA using the benzophenone cross-linking group as described in Example 2.

10 2 Location corresponds to the amino acid residue positions of the *Pseudomonas* pilin protein sequence described by Sastry et al., FEBS Lett. (1983) 151: 253-256.

15 EXAMPLE 2: POLYPEPTIDE-CARRIER COUPLINGS

The peptides were conjugated to keyhole limpet hemocyanin at bovine serum albumin via a linker consisting of a norleucine spacer and a benzophenone cross-linking group (benzoyl benzoic acid), which was added to the peptide during synthesis while the peptide was still on the solid matrix. The protein (≈ 3 mg) was first dissolved in 10 to 20 μ L of water in a test tube. The protein carriers (10 mg/100 μ L) were then added and mixed. Covalent attachment of the peptide to the carrier occurred following activation of the benzoylbenzoyl group by UV irradiation at 4°C for 1 hour in a RPR 208 preparative reactor (Rayonet, The Southern New England Ultraviolet Co., Middletown, Conn.) equipped with RPR-350 mm lamps. Unconjugated haptens were removed by successive dialysis against 8 M urea, 10 mM ammonium bicarbonate, and 25 mM ammonium bicarbonate. The product was freeze-dried. The peptide incorporation was determined by hydrolysis of a small sample of the conjugate and calculating the ratio of the residue norleucine with respect to any reference amino acid not found in the peptide sequence but contained in the sequence of the carrier molecule. This ratio then

represents the molar ratio of peptide:carrier. Peptide/carrier ratios of about 4:1 and 10:1 were obtained for the oxidized and reduced peptides, respectively.

5

EXAMPLE 3: SCREENING OF RABBIT SERA FOR ANTI-POLYPEPTIDE ANTIBODIES

Rabbit anti-sera were screened for the presence of anti-polypeptide antibodies using an enzyme linked immunosorbent assay (ELISA). Polypeptide antigen made as described in Example 1, above, was adsorbed onto the walls of microtiter plate wells to provide solid phase bound target antigen.

A solution of conjugate (5 $\mu\text{g/mL}$) dissolved in coating buffer, sodium carbonate, pH 9.6, was used to coat the wells of a microtiter plate. The individual wells were coated with 120 μL of this solution in a humidified chamber at 4°C for 16 hours. These plates were then washed with phosphate buffer saline/Tween three times.

Non-specific binding sites on the microtiter well walls were thereafter blocked by incubating 50 μL of 3% (w/v) BSA/PBS in each well for 4 hours at 37°C in a humidified chamber. After incubation, excess BSA was removed by inverting and shaking the plates. Polypeptide bound to a solid support whose non-specific binding sites had been blocked was thus provided for use as target antigen.

To assay the rabbit sera for the presence of anti-polypeptide antibodies, an aliquot of each serum was serially diluted ten-fold in 1% (w/v) BSA/PBS. One hundred microliters of each dilution was contacted with solid phase bound polypeptide by a mixture in the appropriate microtiter wells prepared above. Contact was maintained by incubating the wells for about 2 hours at 37°C in a humidified chamber, thus allowing any anti-polypeptide antibodies present in the serum

dilutions to immunoreact with solid phase bound polypeptide target antigen. After incubation, the solid and liquid phases were separated by filling the wells with phosphate buffered saline/Tween inverting and shaking 3 times in seriatim.

To detect the presence of an immunoreaction between anti-polypeptide antibodies and solid-phase antigen, 100 μ L of a 1:1000 dilution of goat anti-rabbit IgG labelled with alkaline phosphatase (Boehringer-Mannheim Biochemicals, Indianapolis, Indiana) in phosphate buffered saline/Tween, was added to each well and incubated for about 2 hours in a humidified chamber at room temperature. The wells were washed three times with phosphate buffered saline/Tween in seriatim. A substrate solution (50 μ L) containing 1 mg of p-nitrophenylphosphate in 1 mL of 10% diethanolamine, pH 9.8, was added to each well and the reaction was allowed to continue for about 45 to 60 min. at room temperature. The amount of indicating reaction (color development) was quantitated by measuring the absorbance of each well at 405 nm. Rabbit antisera demonstrating an absorbance which was 0.05 units above background were determined and the results are tabulated in Table 2.

25

TABLE 2

End Point Titers - Direct Elisa Using Rabbit Antisera Against Peptide Conjugate

	<u>Designation¹</u>	<u>Peptide-Conjugate Titer</u>
	17-R1	3.5 x 10 ⁻⁶
30	17-R2	7.1 x 10 ⁻⁶
	17-01	4.5 x 10 ⁻⁶
	17-02	2.1 x 10 ⁻⁶

1 Antisera derived from 4 different rabbits.

35

**EXAMPLE 4: SCREENING OF RABBIT SERA FOR ANTI-PILIN
ANTIBODIES**

Rabbit antisera were screened for binding to *Pseudomonas pili* isolated from two strains, PAK and PAO, using direct enzyme-linked immunoabsorbent assay (ELISA). The pili were isolated and purified as described by Paranchych et al., Can. J. Microbiol. (1979) 25: 1175-1181 and described in Example 5. A 5 µg/mL solution of pili dissolved in coating buffer sodium carbonate, pH 9.6, was used to coat the wells of a microtiter plate. The individual wells were coated with 120 µL of this solution in a humidified chamber at 4°C for 16 hours. These plates were then washed with phosphate buffered saline/Tween three times.

Non-specific binding sites on the microtiter well walls were thereafter blocked by incubating 50 µL of 3% (w/v) BSA/PBS in each well for 4 hours at 37°C in a humidified chamber. After incubation, excess BSA was removed by inverting and shaking the plates. Polypeptide bound to a solid support whose non-specific binding sites had been blocked was thus provided for use as target antigen.

To assay the rabbit sera for the presence of anti-polypeptide antibodies, an aliquot of each serum was serially diluted 10-fold in 1% (w/v) BSA/PBS. One hundred microliters of each dilution was contacted with solid phase bound polypeptide by a mixture in the appropriate microtiter wells prepared above. Contact was maintained by incubating the wells for about 2 hours at 37°C in a humidified chamber, thus allowing any anti-polypeptide antibodies present in the serum dilutions to immunoreact with solid phase bound polypeptide target antigen. After incubation, the solid and liquid phases were separated by filling the wells with phosphate buffered saline/Tween, inverting and shaking 3 times in seriatim.

To detect the presence of an immunoreaction between anti- antibodies and solid-phase antigen, 100 μ L, of a 1:1000 dilution of goat anti-rabbit IgG labelled with alkaline phosphatase (Boehringer-Mannheim Biochemicals, Indianapolis, Indiana) in phosphate buffered saline/Tween, was added to each well and incubated for about 2 hours in a humidified chamber at room temperature. The wells were washed three times with phosphate buffered saline/Tween in seriatim. A substrate solution (50 μ L) containing 1 mg of p-nitrophenylphosphate in 1 mL of 10% diethanolamine, pH 9.8, was added to each well and the reaction was allowed to continue for about 45 to 60 min at room temperature. The amount of indicating reaction (color development) was quantitated by measuring the absorbance of each well at 405 nm. Rabbit antisera demonstrating an absorbance which was 0.05 units above background were determined and the results are tabulated in Table 3.

TABLE 3
End Point Titers (SD) (n = 3) - Direct
ELISA Using Rabbit Antisera Against
Pili from Strains PAK and PAO

5	Designation ¹	<u>Pili Titer</u>	
		<u>PAK</u>	<u>PAO</u>
	17-R1	1.0 x 10 ⁻⁵ (1.2 x 10 ⁻⁵)	4.15 x 10 ⁻⁴ (3.7 x 10 ⁻⁴)
10	17-R2	1.6 x 10 ⁻⁵ (0.4 x 10 ⁻⁵)	4.5 x 10 ⁻⁴ (0.3 x 10 ⁻⁴)
	17-01	1.5 x 10 ⁻⁵ (0.7 x 10 ⁻⁵)	2.0 x 10 ⁻⁵ (0.8 x 10 ⁻⁵)
15	17-02	2.0 x 10 ⁻⁵ (1.2 x 10 ⁻⁵)	1.3 x 10 ⁻⁴ (1.6 x 10 ⁻⁴)

- 20 1 Antisera derived from 4 different rabbits.
2 The endpoint (n = 3) was determined as the cutoff at
an A405 of 0.05 AU.

EXAMPLE 5: PURIFICATION OF PILI

25 The purification procedure used was previously
described by Paranchych et al., Can. J. Microbiol. (1979)
25: 1175-1181. Bacteria were grown on solid medium in
large pans as described above and then harvested by
scraping the surface of the agar and suspending the cells
30 from 36 trays (about 100 g wet weight) in 1000 mL SSC
buffer. The cells were then stirred with a magnetic
stirrer at 5°C for 2 h. Large bits of agar were removed
by passing the suspension through a sieve and the pili
were removed from the cells by blending in 200 mL
35 portions for 2 min at 2000 rpm with a Sorvall Omnimixer.
After removing bacteria by centrifugation at 10,000 x g
for 15 min. the NaCl concentration of the supernatant
solution was adjusted to 0.5 M. Polyethylene glycol 6000
(PEG 6000) was then added to a final concentration of 1%
40 w/v, and the solution was allowed to sit for 18 h at 4°C.
Both pili and flagella precipitated under these
conditions and were removed by centrifugation at 7000 x g

for 20 min. To remove flagella, the pellet was resuspended in a 10% w/v $(\text{NH}_4)_2\text{SO}_4$ solution (pH 4.0) and allowed to stand at 4°C for 2 h. Pili precipitated under these conditions while flagella remained in suspension.

5 Remaining flagella were removed by repeating the ammonium sulfate precipitation step. The final pellet was redissolved in water, dialyzed exhaustively to remove $(\text{NH}_4)_2\text{SO}_4$, then subjected to CsCl density gradient centrifugation. The latter procedure involved layering

10 20 mL of pili solution onto 16 mL of a preformed step gradient in which the CsCl density ranged from 1.1 to 1.5. After 20 h of centrifugation at 20,000 rpm in an SW27 rotor using a Beckman L2-65B ultracentrifuge, the pilus band (buoyant density of about 1.3 g/cm³) was

15 removed, then subjected to a second CsCl density gradient centrifugation step. After removing the pilus band from the second CsCl gradient and dialyzing to remove CsCl, the pili were resuspended in distilled water and washed by repeated centrifugation for 2 h at 50,000 rpm in a

20 60-Ti fixed-angle rotor. The pili were judged pure when SDS polyacrylamide gel electrophoretic examination of the preparation showed a single protein band of heavily overloaded samples (100 µg pilin per sample).

EXAMPLE 6 : WESTERN BLOT ASSAY

25 The rabbit antisera were further screened to determine their ability to immunoreact with *Pseudomonas* pilin protein in a Western blot assay. *Pseudomonas* pilin protein was isolated from strains PAK and PAO as described in Example 5. Sodium dodecyl

30 sulfate-polyacrylamide gel electrophoresis was carried out according to the Laemmli method by using 15% polyacrylamide running gels. Purified pili (5 µg) and whole-cell lysate (3×10^7 bacteria) were used. The whole-cell lysate was prepared by boiling the PAK cells

35 for 2 to 3 min in 100 µL of sample buffer (2.5% sodium dodecyl sulfate in 0.25 M Tris, pH 6.8) used to dissolve proteins to be loaded onto the sodium dodecyl

sulfate-polyacrylamide gel. The mixture was then centrifuged on a bench-top Microfuge; 10 μ L of the supernatant was removed and diluted with 15 μ L of sample buffer before being loaded onto the gel. After

5 separation, the proteins were transblotted at 0.2 A for 2 to 6 h onto nitrocellulose paper according to the method of Towbin et al., P.N.A.S. (USA) (1979) 76:4350-4354. Excess protein-binding capacity of the nitrocellulose

10 sheet was blocked with 5% gelatin solution (59 gelatin in 100 mL Tris buffered saline, 20 mM Tris, 500 mM NaCl, pH 7.5) for 1 hour at room temperature. The nitrocellulose sheet was then washed twice with 0.05% Tween-20 in Tris buffered saline. The sheet was then treated with

15 antipeptide antisera (1:250) diluted with 1% gelatin in Tris buffered saline containing Tween-20 at room temperature for 16 hours. Excess sera was removed by washing twice with Tris buffered saline containing

20 Tween-20. The pilin bands were detected with an immunoassay kit (BioRad Laboratories, Richmond, California) by using a goat anti-rabbit IgG alkaline phosphatase conjugate diluted 3000-fold with 1% gelatin in Tris buffered saline containing Tween-20. Incubation with this conjugate was carried out at room temperature for 1 hour. Excess conjugate was removed from the sheet

25 by two washes with Tris buffered saline containing Tween-20 followed by one wash with Tris buffered saline alone. Immunoreactants were detected using p-Nitro blue Tetrazolium chloride in the presence of

30 5-Bromo-4-chloro-3-indolyl phosphate toluidine salt. Immunoreactants appear as purple red bands. The results are shown in Table 4.

TABLE 4

Results of Immunoblot Analysis of PAK and
PAO Pilin Proteins with Peptide-Conjugate
Rabbit Antisera

5	<u>Designation</u> ¹	<u>Pilin</u>	
		<u>PAK</u>	<u>PAO</u>
	17-R1	+++ ²	+
	17-R2	+++	+
	17-01	+++	++
10	17-02	+++	+
	1	Antisera derived from 4 different rabbits.	
	2	+++ , intense band; ++ , moderately intense band; + , weak band.	

15 EXAMPLE 7: BUCCAL EPITHELIAL CELL PREPARATION

BEC's were collected from ten healthy non-smoking male volunteers via wooden application sticks rubbed gently on the inside of cheeks, three wooden application sticks per cheek. These sticks were rubbed gently together in 30 mL phosphate buffered saline to suspend the BEC's. These cells were washed three times with 30 mL phosphate buffered saline by successive centrifugation (650 x g spins) and resuspended. The final pellet was suspended in 5 mL phosphate buffered saline at pH 7.2. This suspension was filtered (prewetted 70 μ m nylon mesh) and the cells were diluted to a final concentration of 2 x 10⁵ cells/mL in phosphate buffered saline at pH 7.2. This suspension is stored at 4°C until ready for use.

25 EXAMPLE 8: TRACHEAL EPITHELIAL CELL PREPARATION

Human ciliated tracheal epithelial cells (TECs) were obtained from patients in the Surgical Intensive care unit at Toronto General Hospital by bronchoscopic brushing of the bronchial mucosa as described by Franklin et al., Infection and Immunity (1987) 55, 1523-1525.

TECs were obtained by bronchoscopy from surgical patients (under general anesthetic), intubated intensive care unit (ICU) patients, and health volunteers. For the

surgical and ICU patients, bronchoscopy was performed with a flexible Olympus Type 2 BF bronchoscope inserted through an endotracheal tube. A cytology brush was used to abrade the tracheal-bronchial mucosa, and TECs were collected in high-glucose Dulbecco modified Eagle medium containing 1% sodium citrate.

The cell suspension obtained by bronchoscopy contained both ciliated and nonciliated cuboidal and columnar epithelial cells in addition to various amounts of mucus, erythrocytes, granulocytes, and cell debris and was not suitable for direct use in an adhesion assay. The cell suspension was vortexed briefly, sequentially passed through 70- and 30- μ -pore-size-mesh nylon screens, washed twice (500 x g for 15 min at 4°C) with 10 l of 0.01 M phosphate-buffered saline (pH 7.2) (PBS), and then resuspended in 1 ml of PBS. The cell suspension was then fractionated by density gradient centrifugation (500 x g for 15 min at 4°C in a swinging bucket rotor) on a PBS-preformed (48,000 x g for 40 min at 4°C) 65% (vol/vol) percoll gradient. The TEC band was collected and applied to a second percoll gradient. The ciliated TEC band was collected from the second gradient, and the cells were washed once in PBS and then resuspended in 1.5 ml of PBS. A direct cell count was performed with a hemacytometer; cell viability was determined by trypan blue dye exclusion. The cell fractionation procedure typically yielded $(2.08 \pm 0.34) \times 10^5$ cells (mean \pm standard error), of which $32.8 \pm 6.5\%$ were ciliated TECs. The vast majority of these cells were viable, and in many cases the cilia were still beating. The fractionated TECs contained only epithelial cells, were essentially free of contaminating mucus, and were used directly for adhesion assays.

EXAMPLE 9: PAK 128-144 BINDING TO BECs

An immunoassay was performed to assess the binding of PAK 128-144 red and PAK 128-144 ox to BECs. BECs ($0.2 \text{ ml at } 2.0 \times 10^5 \text{ BECs/ml}$) were added to an equal volume of

synthetic peptide (0 nmol/ml to 120 nmol/ml) in PBS and incubated at 37°C and agitated at 300 rpm. After 1 h, BECs were collected by centrifugation (13,000 x g for 2 min at room temperature) and washed 5 times with PBS.

5 Monoclonal antibody PK99H (0.2 ml of a 10^{-3} dilution in PBS of purified IgG with a titre of 10^6) was added to the BEC pellet and incubated as described above for 1 h. The BECs were then collected by centrifugation (13,000 x g for 2 min at room temperature) and washed 5 times with

10 PBS. Goat anti-mouse IgG (H+L) immunoglobulin G-peroxidase conjugate (Jackson Laboratories) was added to the BEC pellet (0.2 ml of a 1:10000 dilution in PBS) and the mixture incubated as described above for 1 h. The BECs were collected by centrifugation (13,000 x g for 2 min at

15 room temperature) and washed 5 times with PBS. The pellet was resuspended in 0.2 ml of 1 mM ABTS (2,2'-azino-di-(3-ethylbenzthiazoline sulfonic acid)) in citrate buffer pH 4.2 + 0.03% peroxide and transferred to a clean tube. The horseradish peroxidase enzyme reaction

20 was stopped by the addition of 0.2 ml of 4 mM NaN_3 and the optical density at 405 nm was determined after removal of the BECs by centrifugation. The BEC concentration in each tube was determined with a hemocytometer at the end of the assay prior to the removal of BECs by

25 centrifugation. Results are shown in Figure 1 wherein binding of synthetic peptide Ac17red (■) and synthetic peptide Ac17ox (+) to human BECs is plotted. Binding of the synthetic peptides to BECs was determined by a whole cell ELISA assay utilizing the monoclonal antibody PK99H

30 (which binds to both Ac17px and Ac17red) to quantitate the amount of synthetic peptide bound to the surface of BECs.

EXAMPLE 10: PAK 128-144 INHIBITION OF PILUS BINDING TO BECs

35 An immunoassay was performed to assess the effect of PAK 128-144 red on pilus binding to BECs. BECs (0.2 ml at 2.0×10^5 BEC/ml) and synthetic peptide PAK 128-144 red

(0.1 ml such that a final concentration of 0,40,80 or 120 nmol/ml of synthetic peptide was obtained) were preincubated for 30 min at room temperature. Pili (0.1 ml of 0 μ g/ml to 100 μ g/ml) were then added to the BECs with varying concentrations of synthetic peptide (0,40,80 for 120 nmol/ml). The mixtures were then incubated for 2 h at 37°C while being agitated at 300 rpm. BECs and bound pili were then collected by centrifugation (13,000 x g for 2 min) and washed 5 times with PBS to remove unbound pili. Monoclonal antibody PK3B (0.1 ml of a 10^{-4} dilution in PBS) (this antibody recognizes PAK pili, but does not react with synthetic peptide PAK 128-144) was then added to the BECs with bound pili and incubated for 1 h as described above. The remainder of the immunoassay was the same as described for pilus binding to BECs. Results are shown in Figure 2 wherein a modified Lineweaver-Burk plot of the binding of synthetic peptides Ac17red (■) and Ac17ox (+) to human BECs is plotted, and in Figure 3, wherein a modified Lineweaver-Burk plot of the binding of PAK pili to human BECs in the presence of 0 (X), 40 (X), 80 (D), and 120 () nmoles/ml of synthetic peptide Ac17red are plotted.

EXAMPLE 11: PILI AND PAK 128-144 BINDING TO TECs

TECs (0.1 ml of 1×10^5 cells/ml) were mixed with an equal volume of PAK pili (345 g/ml), PAK 128-144 red (10 nmol/ml), PAK 128-144 ox (50 nmol/ml) or PBS. The mixture was incubated at 37°C for 1 h and agitated at 300 rpm. TECs were then collected by centrifugation (6,000 x g for 1 min at room temperature) and washed 3 times with PBS. Anti-pilus monoclonal antibodies PK3B (0.1 ml of a 10^{-4} dilution of purified IgG with a titre of 10^8 in PBS) or monoclonal antibody PK99H (0.1 ml of a 10^{-3} dilution of Purified IgG with a titre of 10^6 in PBS) were added to TECs incubated with pili or synthetic peptides PAK 128-144 red and PAK 128-144 ox, respectively (PK3B reacts with PAK pili without affecting pilus binding activity, but PK3B does not react with either PAK 128-144 red or

PAK 128-144 ox). Control preparations included monoclonal antibodies PK3B and PK99H incubated TECs in PBS without the presence of pili and synthetic peptides. TECs were then collected by centrifugation and washed 3 times with PBS. Rabbit anti-mouse IgG, IgM (H + L) affinity purified IgG conjugated to fluorescein isothiocyanate (Cedarlane laboratories) in PBS (0.1 ml of a 1/100 dilution) was added to the washed TECs preparations and incubated for 30 min at 37°C and agitated at 300 rpm. The TECs were washed 3 times as described above and resuspended in 0.1 ml of PBS. Wet mounts were prepared, and examined by epifluorescence and phase contrast microscopy using a Lietz Laborlux equipped with a MPS4 camera system. Photographs were recorded with Kodak T-Max film. Results are shown in Figure 4 wherein indirect immunofluorescent localization of PAK pili binding to fractionated ciliated TECs A) phase contrast micrograph of TEC with bound PAK pili; B) immunofluorescent micrograph of PAK pili bound primarily to the cilia and luminal portion of the cytoplasmic membrane of the same ciliated TECs visualized by phase contrast microscopy in A, C and D are the phase contrast image and the immunofluorescent image of a control TEC exposed to monoclonal antibody PK3B and FITC conjugated anti-mouse but not exposed to PAK pili. Further results are shown in Figure 5, wherein indirect immunofluorescent localization of binding of synthetic peptides Ac17ox (A and B) and Ac17red (C and d) to human ciliated TECs. Micrographs E and F are control preparations not exposed to the synthetic peptides but exposed to monoclonal antibody PK99H and FITC conjugated anti-mouse IgG. Figures A, C and E are phase contrast micrographs of the same cells visualized by immunofluorescence microscopy in Figures B, D and F. Note that synthetic peptide Ac17ox and Ac17red both bind primarily to the cilia and the luminal portion of the cytoplasmic membrane of TECs. The apparent limited binding of Ac17ox to the TECs is due to

the lesser affinity of monoclonal antibody PK99H for oxidized form of the peptide relative to the reduced form of the peptide.

5 EXAMPLE 12: PAK 128-144 BINDING TO BEC BLOTS

 The discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) described by Laemmli and Favre, J. Mol. Biol. (1973) 80: 575-599 was employed. SDS-PAGE of BECs was performed as described above using 8% acrylamide gels. BECs (2 x 10⁵ cells/ml) were solubilized at 100°C for 15 min in 2% (wt/vol.) SDS, 5% (vol/vol) β-mercaptoethanol, 10% (vol/vol) glycerol in 0.625 mM Tris buffer pH 6.8. Solubilized BECs (25 μl) were loaded on the gel and electrophoresed at 20 mA/gel (constant current). Electrophoretically separated material was transferred to nitrocellulose (Schleicher & Schuell) by electrophoretic transfer as described by Towbin et al., P.N.A.S. (U.S.A.) (1979) 76: 4350-4354. After transfer nitrocellulose blots were blocked with 3% (wt/vol) BSA, 0.25% (wt/vol) gelatin, 0.1% (vol/vol) normal rabbit serum, 0.05% (vol/vol) Nonidet P-40, 5 mM EDTA, 150 mM sodium chloride in 50 mM Tris buffer pH 7.5 at 37°C for at least 3 h.

25 Before use blots were rinsed with PBS. Blots were then incubated with PAK 128-144red (0 to 20 nmol/ml) at 37°C shaking at 100 rpm. After 2 h, blots were washed 3 times with BBBB (TTBS) (10 min per wash). Murine monoclonal antibody PK99H (10⁻⁴ dilution in TTBS) (this monoclonal antibody recognizes the PAK 128-144 synthetic peptide) was incubated with the blot at 37°C for 1 h at 100 rpm. The blot was then washed 3 times with TTBS. A goat anti-mouse IgG (H +L) immunoglobulin-alkaline phosphatase conjugate (Jackson Laboratories) in TTBS was added and incubated for 1 h as above. The blot was washed 3 times with TTBS and once with Tris buffered saline. A substrate solution (NBT/BCIP) consisting of

35

0.33 mg/ml nitro blue tetrazolium chloride, 0.165 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate, 100 mM sodium chloride, 5 mM magnesium chloride in 100 mM Tris buffer pH 9.5 was added and color development stopped by rinsing the blot in distilled water. Results are shown in Figure 4, wherein binding of PAK pili and synthetic peptide Ac17red to blotted BEC proteins on nitrocellulose is plotted. Binding of synthetic peptide to the immobilized proteins was assessed (following blocking of the nitrocellulose with BSA) utilizing monoclonal antibody PK99H (or monoclonal antibody PK3B for PAK pili) followed by standard immunoblotting methods. PAK pili at 150 μ g/ml (lane 1), Ac17red at 20 (lane 2), 10 (lane 3), 5 (lane 4), or 0 (lane 5) nmoles/ml was incubated with the blotted BEC protein. BEC proteins oxidized by exposure to 30 mM periodate and then reduced with borohydride before incubation with 20 nmoles/ml of Ac17red (lane 6) or buffer (lane 7). Ac17red at 20 nmoles/ml was initially reacted with 100 μ g/ml of Fab fragments of monoclonal antibody PK99H (which binds to synthetic peptide Ac17red) (lane 8) or reacted with 100 μ g/ml of Fab fragments of monoclonal antibody PK41C which does not bind to synthetic peptide Ac17red (lane 9). Amido black stained BEC proteins (lane 10). Standard molecular weight markers stained with amido black (lane S).

EXAMPLE 13: PERIODATE OXIDATION OF BEC BLOTS

Periodate oxidation (30 mM periodate) and subsequent potassium borohydride reduction of BEC blots was performed as described by Woodward et al., J. Immunol. Meth., 78: 143-153 (1985). One or two cycles of oxidation-reduction were done on preblocked blots. Blots were assessed for synthetic peptide binding as described above in Example 12. Results are also shown in Figure 4.

EXAMPLE 14: INHIBITION OF PILUS BINDING TO BECs

An equal volume of Fab fragments of affinity purified IgG specific for the various synthetic

peptide-BSA conjugates in PBS (0.1 ml at 0.3 - 0.61 mg/ml) was added to purified PAK pili (0.1 ml at 100 ug/ml) and incubated at room temperature for 30 min. To this BECs (0.2 ml at 2.0×10^5 BECs/ml) were added and the mixture incubated at 37°C, shaking at 300 rpm in a New Brunswick gyroshaker. After 2 h, BECs were collected by centrifugation (13 000 Xg for 2 min) and washed 5 times with PBS. Monoclonal antibody PK3B (0.2 ml of a 10-4 dilution in PBS) was added to the BEC pellet and incubated as described above for 1 h. The BECs were then collected by centrifugation and washed 5 times with PBS. Goat anti-mouse IgG Fc-specific immunoglobulin G-peroxidase conjugate (Jackson Laboratories) was added to the mixture incubated as described above for 30 min. The BECs were collected by centrifugation and washed 5 times with PBS. The pellet was resuspended in 0.2 ml of ABTS (2,2'-azino-di-(3-ethylbenzthiazoline sulfonic acid)) in citrate buffer pH 4.2 + 0.03% peroxide and transferred to a clean tube. The reaction was stopped by the addition of 0.2 ml of 4 mM NaN₃ and the optical density at 405 nm was determined after removal of the BECs by centrifugation. The BEC concentration in each tube was determined with a hemocytometer at the end of the assay prior to the removal of BECs by centrifugation.

TABLE 5

Results of Inhibition Studies:
 FAB Fragments Produced from Polyclonal
 Antisera Raised in Rabbits to the
 Synthetic Peptide 128-144 from PAK Pilin Sequence

	Protein (mg/ml) ²	% of Control	S.D. ³	Abs 405 nm ¹	S.D.	
10						
	128-144 r1	0.43	72.03	4.89	0.547	0.034
	128-144 r2	0.55	62.30	0.13	0.473	0.001
	128-144 o1	0.45	70.62	2.53	0.563	0.018
	128-144 o2	0.61	35.68	7.60	0.271	0.053
15	Preimmune	0.30	100.00	13.91	0.759	0.098
	PK99H	0.05	64.62	2.47	0.490	0.017
	Control	0.00	92.66	11.33	0.703	0.080

- End point titration by ELISA of all Fabs at all
 concentrations shows was approximately 10³
1. Corrected for background.
 2. Protein measured by Folin-Lowry using BSA as standard.
 3. Experiments were done in triplicate and whole experiments were replicated 3 times.

EXAMPLE 15: PREPARATION OF FAB FRAGMENTS

Fab fragments were prepared using immobilized papain (Pierce). Briefly, affinity purified antibody was
 dialyzed against 20 mM cysteine HCl, 10 mM tetrasodium ethylenediaminetetraacetic acid (EDTA) in 20 mM sodium phosphate buffer pH 6.2. Antibody (1 ml containing approximately 2 mg antibody) was added to 0.5 ml immobilized papain and incubated at 37°C for 20 h with shaking at 150 rpm. The immobilized papain was removed by centrifugation and the supernatant containing the Fab

fragments diluted with 1 ml of PBS. The Fab fragments were purified by HPLC using a protein G column eluted with PBS. Fab fragments were collected in the flow through, while Fc fragments were eluted from the column with 10 mM glycine pH 2.75. Fab fragments were concentrated by placing the Fab effluent in dialysis tubing (molecular weight cutoff of < 8000) and extracting liquid from the dialysis sack using polyethylene glycol (molecular weight of 15,000 - 20,000). The fragments were then dialyzed against PBS. Activity of Fab fragments was checked by ELISA and production of FAB fragments confirmed by SDS-PAGE.

EXAMPLE 16: EFFECT OF FAB FRAGMENTS TO THE SYNTHETIC PEPTIDE CONJUGATES CORRESPONDING TO AMINO ACID SEQUENCES OF PAK PILIN ON PAK PILI BINDING TO HUMAN BUCCAL CELLS (BECs)

Fab fragments were preincubated with pili before the addition of BECs (1 x 10⁵ cells/mL final concentration) and pili binding was detected using monoclonal antibody PK3B. All Fabs were diluted such that their final titre as measured by ELISA to PAK pili was 103. The results are shown in the bar graph of Figure 7. the bar graph demonstrates that Fab fragments produced against regions other than the C-terminal of PAK pilin are ineffective at preventing pilin binding to BECs. The most effective fragments are r1, r2, 01 and 02, directed at residues 128-144, which reduce pilin binding to 40% to 70% of the control and preimmune serum. This is similar to the effect shown by Fab 99H which is made from anti-PAK pilin monoclonal antibody PK99H which is also directed at this C-terminal region. This graph helps to demonstrate that the C-terminal loop region, residues 128-144, are specifically involved in pilin binding to BECs. The legend applicable to Figure 7 is as follows: 22 = Fab fragments produced against residues 22-33, 41 = Fab fragments produced against residues 41-49, 58 = Fab

fragments produced against residues 58-70, 75 = Fab
fragments produced against residues 75-84, 89 = Fab
fragments produced against residues 89-99, 107 = Fab
fragments produced against residues 107-116, 117 = Fab
5 fragments produced against residues 117-125, r1 = Fab
fragments produced against residues 128-144 with cysteine
residues in the reduced state, r2 = Fab fragments
produced against residues 128-144 with cysteine residues
in the reduced states, o1 = Fab fragments produced
10 against residues 128-144 with cysteine residues in the
oxidized state, o2 = Fab fragments produced against
residues 128-144 with cysteine residues in the oxidized
state, Pre = Fab fragments produced from the preimmune
sera, 99H = Fab fragments produced from anti-PAK pilin
15 monoclonal antibody PK99H, Cont = No Fab fragments added.

Although preferred embodiments of the invention are
described herein in detail, it will be understood by
those skilled in the art that variations may be made
thereto without departing from the spirit of the
20 invention or the scope of the appended claims.

WE CLAIM:

1. A pure polypeptide which is smaller than a naturally occurring *Pseudomonas* pilin protein, said polypeptide comprising an amino acid residue sequence constituted by

5 at least 12 amino acid residues and up to about 20 amino acid residues, said polypeptide being capable of immunologically mimicking a conserved antigenic determinant site within a semi-variable region of the carboxy-terminal half of a *Pseudomonas* pilin and said

10 polypeptide being responsible for adherence of a naturally occurring *Pseudomonas* bacterium to a corresponding receptor.

2. A pure polypeptide containing no more than about 20

15 amino acid residues and including the amino acid residue sequence, taken from left to right in the direction from amino-terminal to the carboxy-terminal, of the formula:

$$-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-X_{19}-X_{20}-$$

20 wherein:

 - i) X designates an amino acid residue or a blank;
 - ii) a blank which occurs between residues X_n and X_{n+2} , where $n=1$ to 18, results in X_n being connected to X_{n+2} through an amide bond (-CONH-); and,
 - 25 iii) X_1 is the amino acid residue Cysteine (C);
 X_2 is an amino acid residue from the group Glycine (G), Lysine (K), Serine (S) or is a blank;
 X_3 is an amino acid residue from the group Alanine (A) or Isoleucine (I) or is a blank;
 - 30 X_4 is an amino acid residue from the group Serine (S) or Threonine (T) or is a blank;
 X_5 is an amino acid residue from the group Glycine (G), Lysine (K), Serine (S) or is a blank;
 X_6 is an amino acid residue from the group Serine (S) or Threonine (T);
 - 35

X₇ is an amino acid residue from the group Aspartic acid (D), Leucine (L), Asparagine (N), Proline (P) or is a blank;

5 X₈ is an amino acid from the group Alanine (A), Leucine (L), Valine (V) or is a blank;

X₉ is the amino acid Threonine (T) or is a blank;

X₁₀ is an amino acid from the group Alanine (A), Asparagine (N), Glutamine (Q), Tryptophan (W) or is a blank;

10 X₁₁ is an amino acid residue from the group Glycine (G), Tryptophan (W) or is a blank;

X₁₂ is an amino acid residue from the group Aspartic acid (D), Glutamic acid (E), Lysine (K);

15 X₁₃ is an amino acid residue from the group Alanine (A), Glutamic acid (E), Asparagine (N), Proline (P);

X₁₄ is an amino acid residue from the group Lysine (K), Methionine (M), Asparagine (N), Glutamine (Q);

X₁₅ is an amino acid residue from the group Phenylalanine (F), Tyrosine (Y);

20 X₁₆ is an amino acid residue from the group Alanine (A), Isoleucine (I), Leucine (L), Arginine (R), Threonine (T);

X₁₇ is the amino acid residue Proline (P);

25 X₁₈ is an amino acid residue from the group Alanine (A), Lysine (K), Asparagine (N) Serine (S);

X₁₉ is an amino acid residue from the group Glycine (G), Asparagine (N), Threonine (T);

X₂₀ is the amino acid cysteine (C).

30 3. A pure polypeptide of claim 2 and selected from the groups consisting of:

i) C T S D Q D E Q F I P K G C

ii) C K S T Q D P M F T P K G C

iii) C T S T Q E E M F I P K G C

35 iv) C T S N A D N K Y L P K T C

v) C A T T V D A K F R P N G C

vi) C K I T K T P T A W K P N Y A P A N C

vii) C G I T G S P T N W K A N Y A P A N C

viii) C S I S S T P A N W K P N Y A P S N C

and the pharmaceutically acceptable salts thereof.

- 5 4. A peptide vaccine suitable for the prevention of
Pseudomonas infection which comprises a pharmaceutically
acceptable diluent and a polypeptide as defined by claim
1.
- 10 5. A peptide vaccine suitable for the prevention of
Pseudomonas infection which comprises a pharmaceutically
acceptable diluent and a polypeptide as defined by claim
2.
- 15 6. A peptide vaccine suitable for the prevention of
Pseudomonas infection which comprises a pharmaceutically
acceptable diluent and a polypeptide as defined by claim
3.
- 20 7. A peptide vaccine in accordance with claim 4, 5 or 6
in unit dosage form wherein the polypeptide is present in
an amount of about 10 micrograms to about 100 milligrams.
- 25 8. A method of immunizing against a Pseudomonas
infection a susceptible patient which method comprises
administering to the patient an effective amount of
polypeptide defined by claim 1.
- 30 9. A diagnostic system suitable for assaying for
Pseudomonas aeruginosa pilus protein which system
comprises (a) receptor molecules elicited in an animal
host by the polypeptide defined in claim 3 and (b)
indicating means capable of signalling an immunoreaction
of said receptor molecules with the pilus protein.
- 35 10. A receptor raised to the polypeptide defined by
claim 1.

11. The receptor of claim 10 wherein the receptor is a whole antibody.
12. The receptor of claim 10 wherein the receptor is an antibody combining site.
13. A passive vaccine suitable for the prevention of Pseudomonas infection which comprises a pharmaceutically acceptable diluent and a receptor raised to the polypeptide defined in claim 1.
14. A method of immunizing against a Pseudomonas infection a susceptible patient which method comprises administering to the patient a pharmaceutically acceptable diluent and an effective amount of the receptor defined in claims 10, 11, and 12.
15. A receptor vaccine in accordance with claim 13 in unit dosage form wherein the receptor is present in an amount of about 10 micrograms to about 100 milligrams.
16. A method of immunization of claim 8 which comprises administering to the patient said effective amount of polypeptide in a pharmaceutically acceptable diluent.
17. A method of immunization of claim 8 which comprises administering to the patient said effective amount of said polypeptide by expression of said polypeptide in said patient in a compatible non-toxic virus or microorganism, said polypeptide being expressed by replication of said virus or microorganism having a DNA sequence encoding for said polypeptide.
18. A method of immunization of claim 17, wherein said virus is a vaccinia virus.

19. A method of immunization of claim 17, wherein said microorganism is salmonella containing said DNA sequence in a compatible plasmid vector.

5 20. A pure DNA sequence encoding for said polypeptide for use in said virus or microorganism of claim 17, said DNA sequence being selected from the group consisting of the following sequences and their analogues

10 i) PAK C T S D Q D E Q F I P
Cys Thr Ser Asp Gln Asp Glu Gln Phe Ile Pro
TGC ACC AGT GAT CAG GAT GAG CAG TTT ATT CCG

15 K G C
Lys Gly Cys
AAA GGT TGC

20 ii) PAO C K S T Q D P M F T P
Cys Lys Ser Thr Gln Asp Pro Met Phe Thr Pro
TGT AAA TCT ACC CAG GAT CCG ATG TTC ACT CCG

25 K G C
Lys Gly Cys
AAA GGT TGT

30 iii) CD₄ C T S T Q E E M F I P
Cys Thr Ser Thr Gln Glu Glu Met Phe Ile Pro
TGC ACC TCT ACT CAG GAA GAG ATG TTT ATT CCT

35 K G C
Lys Gly Cys
AAG GGT TGT

40 iv) K₁₂ C T S N A D N K Y L P
Cys Thr Ser Asn Ala Asp Asn Lys Tyr Leu Pro
TGT ACT TCC ACC GCA GAT AAC AAG TAC CTG CCA

45 K T C
Lys Thr Cys
AAA ACC TGC

v) KB₇
 5 C A T T V D A K F R P
 Cys Ala Thr Thr Val Asp Ala Lys Phe Arg Pro
 TGT GCT ACT ACC GTA GAT GCT AAA TTC CGT CCT
 M G C
 Asn Gly Cys
 AAT GGC TGT
 10 vi) P₁
 C K I T K T P T A W K
 Cys Lys Ile Thr Lys Thr Pro Thr Ala Trp Lys
 TGC AAA ATC ACC AAA ACT CCT ACA GCT TGG AAG
 15 P N Y A P A N C
 Pro Asn Tyr Ala Pro Ala Asn Cys
 CCC AAC TAC GCT CCG GCT AAT TGC
 20 vii) 492_c
 C G I T G S P T N W K
 Cys Gly Ile Thr Gly Ser Pro Thr Asn Trp Lys
 TGC GGC ATC ACT GGT TCG CCG ACC AAC TGG AAA
 25 A N Y A P A N C
 Ala Asn Tyr Ala Pro Ala Asn Cys
 GCC AAC TAC GCT CCG GCC AAT TGC
 30 viii) TBOU-1
 C S I S S T P A N W
 Lys Ser Ile Ser Ser Thr Pro Ala Asn Trp
 TGC TCG ATC AGT AGC ACT CCT GCT AAC TGG
 35 K P N Y A P S N C
 Lys Pro Asn Tyr Ala Pro Ser Asn Cys
 AAA CCA AAC TAT GCC CCC TCT AAC TGC




FIG. 1






FIG. 2








FIG. 5




FIG. 6

7/7




FIGURE 7

INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 90/00135

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 07 K 7/08, A 61 K 39/00, A 61 K 37/02, G 01 N 33/569														
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding-bottom: 5px;">Classification System </td> <td style="border-bottom: 1px solid black; padding-bottom: 5px;">Classification Symbols</td> </tr> <tr> <td style="border: none; padding: 5px;">IPC⁵</td> <td style="border: none; padding: 5px;">C 07 K, A 61 K, G 01 N</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	C 07 K, A 61 K, G 01 N								
Classification System	Classification Symbols													
IPC ⁵	C 07 K, A 61 K, G 01 N													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category ⁶</th> <th style="width: 60%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X, Y P</td> <td style="vertical-align: top;">Chemical Abstracts, vol. 110, 1989, (Columbus, Ohio, US) K.K. Lee et al.: "Immunological studies of the disulfide bridge region of Pseudomonas aeruginosa PAK and PAO pilins, using anti-PAK pilus and antipeptide antibodies", see page 545, abstract no. 152346v & Infect. Immun. 1989, 57(2), 520-6 --</td> <td style="text-align: center; vertical-align: top;">3-14</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;">Chemical Abstracts, vol. 100, 1984, (Columbus, Ohio, US) T.H. Watta et al.: "Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili", see page 442, abstract no. 66284k & Infect. Immun. 1983, 42(1), 113-21 --</td> <td style="text-align: center; vertical-align: top;">3-14</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;">EP, A, 0117367 (SCRIPPS) 5 September 1984, see pages 1-15, 22-61, 130-159 --</td> <td style="text-align: center; vertical-align: top;">3-14</td> </tr> </tbody> </table>			Category ⁶	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X, Y P	Chemical Abstracts, vol. 110, 1989, (Columbus, Ohio, US) K.K. Lee et al.: "Immunological studies of the disulfide bridge region of Pseudomonas aeruginosa PAK and PAO pilins, using anti-PAK pilus and antipeptide antibodies", see page 545, abstract no. 152346v & Infect. Immun. 1989, 57(2), 520-6 --	3-14	Y	Chemical Abstracts, vol. 100, 1984, (Columbus, Ohio, US) T.H. Watta et al.: "Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili", see page 442, abstract no. 66284k & Infect. Immun. 1983, 42(1), 113-21 --	3-14	Y	EP, A, 0117367 (SCRIPPS) 5 September 1984, see pages 1-15, 22-61, 130-159 --	3-14
Category ⁶	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X, Y P	Chemical Abstracts, vol. 110, 1989, (Columbus, Ohio, US) K.K. Lee et al.: "Immunological studies of the disulfide bridge region of Pseudomonas aeruginosa PAK and PAO pilins, using anti-PAK pilus and antipeptide antibodies", see page 545, abstract no. 152346v & Infect. Immun. 1989, 57(2), 520-6 --	3-14												
Y	Chemical Abstracts, vol. 100, 1984, (Columbus, Ohio, US) T.H. Watta et al.: "Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili", see page 442, abstract no. 66284k & Infect. Immun. 1983, 42(1), 113-21 --	3-14												
Y	EP, A, 0117367 (SCRIPPS) 5 September 1984, see pages 1-15, 22-61, 130-159 --	3-14												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding-bottom: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding-bottom: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border: none; text-align: center; padding: 5px;">25th July 1990</td> <td style="border: none; text-align: center; padding: 5px;">04.09.90</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding-bottom: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding-bottom: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="border: none; text-align: center; padding: 5px;">EUROPEAN PATENT OFFICE</td> <td style="border: none; padding: 5px;">F.W. HECK </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	25th July 1990	04.09.90	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	F.W. HECK				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
25th July 1990	04.09.90													
International Searching Authority	Signature of Authorized Officer													
EUROPEAN PATENT OFFICE	F.W. HECK													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP, A, 0279151 (TRION FORSKNING- OCH UTVECKLINGS AB) 24 August 1988, see the whole document --	3-14
A	EP, A, 0153710 (TOHO YAKUHI KOGYO K.K.) 4 September 1985, see the whole document --	3-14
A	EP, A, 0259149 (THE UNIVERSITY OF SASKATCHEWAN) 9 March 1988, see pages 1-10, 22; figure I --	3-14
A	WO, A, 85/05037 (SYNTEK) 21 November 1985, see pages 1-7, 66-73 -----	3-14

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

CA 9000135

SA 36465

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/08/90
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0117367	05-09-84	US-A- 4545931	08-10-85
		US-A- 4603049	29-07-86
		AU-B- 572821	19-05-88
		AU-A- 2436884	02-08-84
		JP-T- 60501360	22-08-85
		US-A- 4758655	19-07-88
		WO-A- 8402700	19-07-84
		US-A- 4886663	12-12-89
		AU-A- 3747185	26-06-85
		EP-A- 0165307	27-12-85
		JP-T- 61500664	10-04-86
		WO-A- 8502611	20-06-85
EP-A- 0279151	24-08-88	AU-A- 1089188	15-07-88
		SE-A- 8605513	23-06-88
		WO-A- 8804665	30-06-88
		SE-B- 457353	19-12-88
		SE-A- 8700761	23-06-88
EP-A- 0153710	04-09-85	JP-A- 60178824	12-09-85
		JP-A- 60178825	12-09-85
		US-A- 4575459	11-03-86
EP-A- 0259149	09-03-88	AU-A- 7791887	10-03-88
		JP-A- 63218627	12-09-88
WO-A- 8505037	21-11-85	AU-B- 593770	22-02-90
		AU-A- 4299485	28-11-85
		EP-A- 0179887	07-05-86
		JP-T- 62501355	04-06-87
		US-A- 4795803	03-01-89

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)